Review

Available online at
www.heca-analitika.com/hjas

Heca Journal of Applied Sciences

Vol. 3, No. 1, 2025

Prostate Cancer Vaccines: Progress, Challenges, and Future Directions

Stefanus Vicky Bernhard Elisa Runtunuwu [1], Trina Ekawati Tallei [2,3,*] and Grace Lendawati Amelia Turalaki [2]

[1] Faculty of Medicine Student, Sam Ratulangi University, Manado 95115, Indonesia; stefanusruntunuwu011@student.unsrat.ac.id (S.V.B.E.R.)
[2] Department of Biology, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia; trina_tallei@unsrat.ac.id (T.E.T.); gracelat@unsrat.ac.id (G.L.A.T.)
[3] Department of Biology, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado 95115, Indonesia

* Correspondence: trina_tallei@unsrat.ac.id

Article History

Received 19 January 2025
Revised 4 March 2025
Accepted 10 March 2025
Available Online 19 March 2025

Keywords:
Prostate cancer
Cancer vaccines
Immunotherapy
Tumor antigens
Immunotherapy advancements

Abstract

Prostate cancer remains a major contributor to cancer-related deaths in men, with its incidence rising significantly with age. Conventional treatment modalities, including surgery, radiation therapy, hormonal therapy, and chemotherapy, often face limitations such as treatment resistance, disease recurrence, and considerable side effects. These challenges have sparked growing interest in novel approaches like immunotherapy, which leverages the immune system to combat cancer. Among these, vaccine-based immunotherapy has emerged as a promising strategy, aiming to generate precise immune responses against tumor-specific antigens. Advances in immunology, molecular targeting, and vaccine development have demonstrated encouraging results in terms of safety and immunogenicity. Nevertheless, obstacles such as tumor heterogeneity, immune escape mechanisms, and limited efficacy in advanced stages of the disease continue to hinder progress. The aim of this review is to examine the current landscape of prostate cancer vaccine development, with a focus on advancements in molecular target identification, optimization of vaccine technologies, and the evaluation of combination therapy strategies. Findings from clinical trials have shed light on both the opportunities and challenges of vaccine-based therapies. Synergistic approaches involving immune checkpoint inhibitors, radiotherapy, and androgen deprivation therapy have shown potential to amplify immune responses and mitigate resistance mechanisms. Additionally, emerging technologies such as bioinformatics and artificial intelligence are revolutionizing vaccine development by enabling the discovery of patient-specific neoantigens and the creation of tailored vaccine formulations. Despite these breakthroughs, achieving consistent therapeutic outcomes remains challenging, particularly in metastatic and castration-resistant cases. Future directions in the field include developing personalized cancer vaccines, adopting adaptive clinical trial designs, and employing innovative endpoints to streamline translation into clinical practice. In summary, while prostate cancer vaccine development has advanced significantly, addressing critical barriers like tumor heterogeneity and immune evasion and embracing emerging technologies are essential for optimizing personalized vaccines and improving treatment outcomes.

1. Introduction

Prostate cancer is among the most prevalent cancers in men globally and is a significant contributor to cancer-related deaths, ranking second only to lung cancer in men [1–3]. Its incidence increases sharply with age, with studies indicating undiagnosed cases in up to 60% of men over 80 [4, 5]. The high prevalence of prostate cancer, combined with its significant morbidity and mortality, poses substantial challenges for both patients and healthcare systems worldwide [6]. Conventional treatment options, including surgery, radiation therapy, hormonal therapy, and chemotherapy, are often limited by drug resistance, severe side effects, and disease recurrence, underscoring the need for more effective therapeutic approaches [7, 8]. Despite advancements in prostate cancer treatment, several unmet clinical needs remain unresolved. Although systemic treatments can slow disease progression, their tumor control is often temporary and comes with significant toxicity [9–12]. Over time, many patients develop castration-resistant prostate cancer (CRPC), in which the disease advances despite ongoing hormone therapy [9]. One of the most significant obstacles in prostate cancer treatment is its immunosuppressive tumor microenvironment (TME), which weakens natural immune responses and limits the efficacy of immunotherapies [13–16]. Overcoming these challenges requires novel strategies that can induce a robust and sustained antitumor immune response. Unlike conventional cytotoxic treatments that directly attack tumor cells, vaccines are designed to train the immune system to recognize and eliminate cancer cells with greater precision [17–19]. In this context, therapeutic cancer vaccines introduce a transformative approach by utilizing the immune system to elicit targeted and long-lasting tumor destruction, reducing off-target effects and potentially offering long-term tumor control with fewer adverse consequences [20, 21].

Recent technological breakthroughs have propelled prostate cancer vaccine development, offering new opportunities to overcome these barriers. Advances in tumor antigen discovery have identified prostate-specific targets such as PSMA, PAP, and TMPRSS2:ERG, allowing for the design of more precise immunotherapies [22, 23]. Innovations in vaccine platforms, including dendritic cell-based vaccines, mRNA vaccines, viral vector vaccines, and peptide-based formulations, have expanded the scope of vaccine-induced immune responses. Additionally, the integration of immune checkpoint inhibitors (ICIs) (e.g., anti-PD-1, anti-CTLA-4) with vaccines has shown promise in enhancing T cell activation and overcoming immune suppression. Emerging AI-driven antigen selection and personalized vaccine design are further refining vaccine development by predicting highly immunogenic epitopes and tailoring formulations to individual patient profiles. Given these advancements, prostate cancer vaccines hold great promise as both an alternative and a complementary approach to existing therapies. This review explores the current landscape of prostate cancer vaccine development, key clinical challenges, and emerging strategies aimed at optimizing vaccine efficacy and clinical translation.

2. Immunological Foundations of Prostate Cancer Vaccines

2.1. Immunopathology of Prostate Cancer

Prostate cancer poses a significant challenge for immunotherapy due to its highly immunosuppressive tumor microenvironment. This microenvironment is dominated by regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells, as well as immunosuppressive molecules such as adenosine and TGF-beta, which collectively hinder immune responses [24, 25]. Additionally, the low mutational burden of prostate cancer further reduces its immunogenicity, complicating efforts to stimulate robust immune activity [26].

Inflammation and infection may also contribute to the disease's pathogenesis, adding another layer of complexity. Chronic inflammation plays a dual role in prostate cancer progression. While inflammation is generally associated with immune activation, persistent inflammation in the prostate can paradoxically promote tumor progression by fostering an immunosuppressive microenvironment [27]. Prolonged exposure to inflammatory cytokines can recruit immunosuppressive cells, including regulatory T cells and myeloid-derived suppressor cells, which inhibit cytotoxic T cell responses [28]. Furthermore, the presence of chronic inflammation has been linked to increased genomic instability and the upregulation of immune checkpoints like PD-L1, further dampening immune surveillance [29–35]. These mechanisms highlight the complex interplay between immunosuppression and inflammation in prostate cancer, where vaccines must not only elicit an effective immune response but also overcome these regulatory barriers. Prostate-specific antigen-focused immunotherapy has also shown potential in eliciting meaningful clinical responses in advanced prostate cancer cases.

Although some prostate cancer vaccines have shown potential (e.g., Sipeleucel-T), their efficacy remains marginal, barely meeting clinical benchmarks [36, 37]. To achieve meaningful therapeutic impact, it is crucial to develop strategies that enhance vaccine efficacy beyond



Figure 1. Prostate cancer vaccine immunological principle.

current limitations. Novel approaches are still being explored to counteract the immunosuppressive tumor microenvironment, including the integration of ICIs to sustain T cell activation and adjuvants to boost immune responses as will be explored further in this article. A comprehensive understanding of the immunopathology of prostate cancer is therefore essential for developing effective and innovative immunotherapy approaches.

2.2. Mechanisms Underlying Cancer Vaccine Efficacy

Cancer vaccines offer a promising approach in immunotherapy, aiming to boost the immune system's ability to fight tumors by introducing tumor-specific antigens in various forms. These vaccines aim to overcome immune suppression and activate both humoral and cellular immune responses. Their mechanism of action involves eliciting antigen-specific T-cell responses, stimulating helper T cells, and activating innate immune cells [38, 39].

Researches underscores the pivotal role of both CD4+ and CD8+ T cells in cancer immunotherapy, with CD4+ T cells contributing to antigen presentation, T cell activation, and immune memory while sometimes proving more effective than CD8+ T cells in tumor rejection [40, 41]. CD8+ cytotoxic T lymphocytes (CTLs) serve as the primary effectors of antitumor immunity by directly killing cancer cells (Figure 1) [42]. Once activated, CD8+ T cells recognize tumor-associated antigens (TAAs) presented by major histocompatibility complex (MHC) class I molecules on the surface of cancer cells [43]. Upon binding to the antigen, they release perforin and granzymes, inducing apoptosis in target cells [44]. The strength and persistence of the CD8+ T cell response correlate with better clinical outcomes, making their activation a critical goal for therapeutic cancer vaccines. However, CD8+ T cells alone are often insufficient in mounting a sustained antitumor response, particularly in immunosuppressive tumor microenvironments like that of prostate cancer.

Recent animal studies further reinforce this limitation, revealing that even a large in vivo population of tumor-reactive CD8+ T cells is insufficient to drive clinically significant tumor regression [45, 46]. This is where CD4+ helper T cells play a crucial supportive role. CD4+ helper T cells enhance antigen presentation, providing cytokine support, facilitating immune memory, and even contributing to direct tumor killing [47, 48]. They interact with antigen-presenting cells (APCs), such as dendritic cells, to improve antigen processing and presentation via MHC class II molecules, which is essential for the effective priming of CD8+ T cells [49]. Additionally, CD4+ T cells secrete key cytokines, including IL-2, IFN-γ, and TNF-α, which promote CD8+ T cell proliferation, differentiation, and persistence, thereby strengthening the overall immune response [49]. Their role extends further to facilitating immune memory, as CD4+ T cell assistance is necessary for the formation and maintenance of long-lived memory CD8+ T cells, ensuring prolonged immunity after vaccination. Notably, certain subsets of CD4+ T cells also exhibit cytotoxic properties, directly targeting tumor cells that express MHC class II molecules [50]. This multifaceted involvement highlights the indispensable function of CD4+ T cells in shaping a robust and sustained immune response in cancer immunotherapy.

An ideal prostate cancer vaccine should effectively stimulate both CD4+ and CD8+ T cell responses to maximize clinical efficacy. While vaccines that exclusively target CD8+ T cells can induce cytotoxicity, the absence

of CD4+ T cell support often results in a transient immune response that is insufficient for long-term tumor control. Conversely, vaccines that also engage CD4+ T cells ensure a more sustained immune response by enhancing CD8+ T cell survival, promoting antibody production, and modulating the tumor microenvironment to support immune activation. This insight has driven the development of cancer vaccines targeting both T cell subsets, leveraging MHC class II-restricted tumor antigens to optimize antitumor immunity. By generating effector cells and establishing immunological memory, cancer vaccines could potentially provide long-term protective immunity [51].

Studies are increasingly focused on enhancing prostate cancer vaccine efficacy by optimizing T cell activation and addressing tumor-induced immunosuppression. Current vaccine candidates, including dendritic cell-based, peptide-based, and DNA/RNA vaccines, aim to stimulate both CD4+ and CD8+ T cells for a stronger and more durable immune response [52, 53]. However, tumor heterogeneity and immune evasion remain major challenges, as prolonged antigen exposure can lead to T cell exhaustion, driven by the upregulation of inhibitory receptors such as PD-1, CTLA-4, TIM-3, and LAG-3 [54–58]. To counteract this, ongoing research integrates ICIs with vaccines to sustain T cell activity and leverages AI-driven epitope selection to identify highly immunogenic targets. These approaches are designed to enhance immune surveillance, reduce tumor immune suppression, and improve long-term vaccine efficacy, as will be explored further later in this article.

2.3. Key Molecular Targets in Prostate Cancer Immunotherapy

Prostate cancer vaccines rely on TAAs to elicit targeted immune responses, but not all antigens are equally effective as vaccine targets. The selection of an ideal antigen is critical for optimizing vaccine efficacy, as the right target can significantly impact immune activation, tumor control, and clinical outcomes. Several key properties define an ideal TAA in prostate cancer immunotherapy are: (1) highly overexpressed in metastatic prostate cancer cells; (2) minimally or not expressed in normal tissues; (3) easily accessible on the cancer cell surface for targeted therapies, and (4) unaffected by androgen regulation [59].

In prostate cancer research, autoantibodies to TAAs, produced by prostate cancer patients, offer a valuable avenue for identifying novel biomarkers [60]. Several promising immunotherapy targets have been discovered and are currently undergoing different stages of preclinical evaluation or clinical trials. Key TAAs, such as PSMA, MUC1, and VEGF/VEGFR, have been studied, and their immunogenic properties are being explored for potential clinical applications [61]. Notably, a recent study identified a prostate-restricted TAA with greater immunogenicity than established antigens like PAP and PSA, showing significant therapeutic potential for metastatic castration-resistant prostate cancer (mCRPC) [62].

Prostate-Specific Membrane Antigen (PSMA) is one of the most promising TAAs in prostate cancer immunotherapy, as it meets all the criteria of an ideal target, including high tumor specificity and consistent overexpression even in advanced metastatic disease [63–66]. Its widespread presence makes it an ideal target for therapeutic vaccines, monoclonal antibodies, and also CAR-T cell therapy. Prostatic Acid Phosphatase (PAP), the antigen used in Sipuleucel-T, was one of the first explored for prostate cancer vaccines, but its low immunogenicity has limited its clinical impact, driving research toward more potent alternatives [67, 68]. Prostate-Specific Antigen (PSA) has also been widely studied, but its expression in both normal and cancerous prostate tissue, as well as its downregulation in aggressive disease, poses challenges for vaccine efficacy [69–71]. To address this, multivalent vaccines targeting multiple antigens have been developed to enhance immune responses and improve treatment durability [72]. Emerging targets, such as the TMPRSS2:ERG fusion protein, offer new opportunities due to their exclusive presence in prostate cancer and stable expression throughout disease progression [23, 73]. Similarly, mucin-1 (MUC1), a glycoprotein involved in tumor growth, has gained attention for its aberrant overexpression in prostate cancer cells, making it a highly promising candidate for vaccine-based immunotherapy [74–76].

Recent advancements in bioinformatics and artificial intelligence (AI) have revolutionized antigen discovery, enabling the identification of novel TAAs and patient-specific neoantigens. AI-driven prediction models analyze tumor genomic and proteomic data to identify unique epitopes with high immunogenic potential [77]. This personalized approach enhances the likelihood of vaccine efficacy by tailoring antigen selection to an individual's tumor profile, reducing the risk of immune escape [78]. Additionally, the concept of "epitope spreading"—where an initial immune response against one antigen broadens to recognize additional tumor antigens—has gained interest in vaccine research [72, 79, 80]. By leveraging this phenomenon, vaccines can induce a more comprehensive and durable immune attack against heterogeneous prostate cancer cells.



Figure 2. Prostate cancer vaccine types.

The success of prostate cancer vaccines hinges on selecting the right molecular targets. PSMA remains a frontrunner due to its specificity and consistent expression, while newer targets like TMPRSS2:ERG and MUC1 offer promising alternatives. Multivalent vaccine strategies, AI-driven antigen discovery, and combination approaches with immune-modulating agents are paving the way for more effective prostate cancer immunotherapies. Moving forward, the integration of personalized antigen selection and combination therapies will be crucial in overcoming tumor heterogeneity and resistance, ultimately improving vaccine efficacy in clinical settings. Preclinical studies in animal models have further demonstrated that immunization with recombinant vectors encoding TAAs elicits robust T-cell-mediated protection against prostate tumor growth, particularly in settings of minimal tumor burden [62]. These findings underscore the potential of TAA-based immunization strategies, such as a prostate cancer vaccine, to improve outcomes in prostate cancer treatment.

3. Types of Prostate Cancer Vaccines

Figure 2 depicts various prostate cancer vaccines, including dendritic cell-based, peptide-based, virus vector-based, RNA-based, and DNA-based types, each of which is discussed in detail in this section.

3.1. Dendritic Cell-Based Vaccines

Dendritic cell (DC)-based vaccines, such as Sipuleucel-T, are patient-specific immunotherapies that utilize ex vivo-modified antigen-presenting cells (APCs) to activate both CD4+ and CD8+ T cell responses. These vaccines have demonstrated robust immune activation and clinical benefits, making Sipuleucel-T the first FDA-approved prostate cancer vaccine. However, their highly complex manufacturing process and high costs have significantly limited widespread adoption [81]. Producing a DC vaccine involves extracting peripheral blood mononuclear cells (PBMCs) from a patient, loading them with a specific tumor antigen, and reinfusing them to elicit an immune response [82]. This patient-specific processing is labor-intensive and expensive, resulting in limited scalability and high treatment costs. Despite these challenges, DC vaccines generate strong, targeted immune responses, making them valuable in personalized cancer immunotherapy. Clinical trials have demonstrated the safety and effectiveness of DC vaccines, showing immune responses in about two-thirds of treated prostate cancer patients and clinical benefits in nearly half [35]. The clinical benefit rate of DC vaccines is 54.2%, with a modest objective response rate of 7.7%, and these outcomes are positively correlated with reductions in PSA levels and the induction of cellular immunity [36]. Higher doses of dendritic cells and the use of mature DCs have been associated with improved clinical outcomes, highlighting the importance of optimizing vaccine protocols [37]. However, subsequent trials with DC-based vaccines have struggled to replicate these clinical successes, further contributing to the limited adoption of Sipuleucel-T in standard clinical practice [29]. Monocyte-derived dendritic cells (MoDCs), a common choice for these vaccines, face challenges such as reduced T-cell stimulation and impaired migration, particularly in patients with advanced cancer [29].

The discrepancy between early successful trials and subsequent setbacks of DC-based vaccines in prostate cancer can be attributed to several factors. Variability in

patient selection played a key role, as early trials often included less advanced disease cases, while later studies focused on immunosuppressed, late-stage patients, where the tumor microenvironment (TME) is more resistant to immune activation. Additionally, differences in dendritic cell manufacturing impacted effectiveness, with some trials using highly functional, mature DCs, while others relied on weaker monocyte-derived DCs (MoDCs) with lower T-cell stimulation potential [83]. The highly immunosuppressive TME in advanced disease further weakened vaccine efficacy, as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and PD-L1 expression suppressed immune responses. Inconsistent clinical endpoints also contributed, with early trials measuring immune activation markers, while later studies focused on overall survival (OS), which is harder to improve with DC vaccines alone. Furthermore, many trials, including those leading to Sipuleucel-T's approval, lacked combination strategies with ICIs or cytokine adjuvants, which might have improved T-cell persistence and tumor infiltration. Finally, logistical and financial challenges limited the widespread adoption of Sipuleucel-T, as its patient-specific production process was costly and difficult to scale [84]. Despite these challenges, emerging technologies such as antibody-antigen conjugates and virus co-delivery systems present promising strategies to enhance DC targeting and in vivo activation [81, 85–88].

3.2. DNA and RNA-Based Vaccines

Innovative DNA and RNA-based vaccines are redefining prostate cancer immunotherapy by harnessing their capacity to elicit precise, antigen-specific immune responses while maintaining safety, scalability, and specificity. Unlike dendritic cell vaccines, these vaccines do not require patient-specific processing, making them moderately complex to manufacture yet highly scalable. These platforms target prostate cancer antigens such as PSA, PSCA, PSMA, and STEAP1, inducing both humoral and cellular immunity [89, 90]. DNA vaccines typically require electroporation or viral vectors for efficient uptake, whereas mRNA vaccines utilize lipid nanoparticle (LNP) carriers to enhance stability and intracellular delivery [91–93]. This approach generates robust immune responses, with strong CD8+ T cell activation and adaptability for CD4+ T cell support, making them highly versatile [94, 95].

DNA vaccines have shown efficacy in preclinical studies, where the inclusion of cytokine gene adjuvants enhanced immune activation [89]. Clinical trials have reported encouraging results, highlighting the potential of DNA vaccines to generate prostate-specific immune responses and reduce tumor burden [96, 97]. RNA-based vaccines, including self-adjuvanted platforms like CV9103 and CV9104, have demonstrated immunogenicity, tolerability, and immune activation in early-phase trials, with significant responses observed in a majority of evaluable patients [90, 98].

Advances in delivery methods, such as MS2 virus-like particles and RNA-pulsed dendritic cells, address challenges like mRNA instability and enhance vaccine potency [99, 100]. Both DNA and RNA vaccines benefit from flexibility in antigen encoding and the ability to target multiple prostate-specific antigens simultaneously. Additionally, mRNA vaccines can be rapidly modified to target specific tumor mutations, offering personalized yet scalable cancer vaccine solutions, making them highly adaptable to the heterogeneous nature of prostate tumors [101]. Despite these advancements, the clinical efficacy of these vaccines in advanced prostate cancer remains modest, necessitating further research to optimize delivery systems, adjuvant combinations, and dosing protocols. By integrating these innovations with ongoing clinical insights, DNA and RNA-based vaccines hold great promise for improving outcomes in prostate cancer immunotherapy.

3.3. Peptide-Based Vaccines

Peptide-based vaccines are designed to elicit targeted immune responses against tumor-specific antigens such as prostate-specific antigen (PSA) and the TMPRSS2:ERG fusion [53, 102]. Peptide-based vaccines, consisting of synthetic tumor antigen fragments, are among the simplest and most cost-effective prostate cancer vaccine platforms. They are easily manufactured through peptide synthesis, making them highly scalable and accessible [103]. However, their immunogenicity depends on patient-specific HLA typing, requiring precise antigen selection for optimal immune activation. These vaccines primarily elicit moderate CD8+ T cell responses, but their efficacy is often enhanced with strong adjuvants such as GM-CSF or Montanide to improve antigen presentation [104–107].

Several clinical trials underscore the potential of peptide vaccines in prostate cancer treatment. A phase I trial of a CDCA1 peptide vaccine in castration-resistant prostate cancer (CRPC) demonstrated safety and cytotoxic T lymphocyte activation [108]. Similarly, an E75 peptide vaccine trial in high-risk prostate cancer patients' post-prostatectomy showed safety, immunogenicity, and potential preventive effects against disease recurrence [109]. Another study employing dendritic cells loaded with a cocktail of prostate cancer-associated peptides in HRPC patients reported temporary PSA declines and

antigen-specific T-cell activation, further validating their feasibility [110].

Despite their affordability and ease of production, no peptide vaccine has yet achieved worldwide regulatory approval. Peptide vaccines face challenges in generating long-term immune memory and may require multiple booster doses to sustain efficacy. Additionally, tumor antigen loss or downregulation in aggressive prostate cancer can reduce their effectiveness, making them more suitable for combination immunotherapy strategies [111, 112]. Advances in immunotherapy, particularly the emergence of ICIs, have created opportunities for combining peptide vaccines with other agents to enhance therapeutic efficacy [113]. While progress in peptide vaccine development continues, the lack of regulatory approval highlights the need for further research to optimize formulations, explore novel targets, and enhance efficacy through combination strategies, including ICIs [113].

3.4. Virus or Vector-Based Vaccines

A virus-based vaccine is a type of immunotherapy that uses viruses as delivery systems, or vectors, to introduce tumor-specific antigens into the body to stimulate an immune response, naturally triggering strong CD4+ and CD8+ immune responses due to their inherent immunogenicity. The manufacturing complexity of viral vector vaccines is moderate, requiring precise genetic engineering and biosafety oversight to ensure stability and minimize unintended immune responses [114, 115]. This platform has shown promising results in prostate cancer immunotherapy, with PROSTVAC, a poxvirus-based vaccine, demonstrating strong T cell activation in early trials [116, 117]. Similarly, cytomegalovirus-based vaccines expressing PSA have shown efficacy in delaying tumor growth in murine models [118]. Additional innovations, such as messenger RNA vaccines packaged in MS2 virus-like particles, have exhibited strong humoral and cellular immune responses, including antigen-specific cytotoxic T-lymphocyte activation in preclinical studies [119]. Clinical trials further underscore the potential of virus-based vaccines. A phase I trial of an adenovirus/PSA vaccine reported safety and immunogenicity, with 68% of patients generating anti-PSA T-cell responses and 55% exceeding expected survival times [120]. In another phase II study, a poxvirus-based vaccine elicited PSA-specific T-cell responses in 46% of patients with minimal toxicity [121]. Oncolytic viruses, including engineered DNA and RNA viruses, have also demonstrated promise in clinical trials, with 58% of patients in phase I studies achieving over a 25% decrease in serum PSA levels without severe toxicity [122]. However, PROSTVAC failed to improve overall survival in Phase III clinical trials, underscoring the challenge of translating strong immunogenicity into clinical benefit due to poor tumor infiltration, antigen escape, lack of immune checkpoint blockade, and the late-stage patient population tested in clinical trials [116, 117]. Additionally, PROSTVAC's trial design as a monotherapy, rather than in combination with ICIs, likely reduced its effectiveness. Another major limitation of this approach is the presence of preexisting immunity against viral vectors, which can reduce vaccine efficacy, particularly with commonly used adenovirus-based platforms [119, 123, 124]. Future prostate cancer vaccine strategies should incorporate multi-antigen targeting, immune checkpoint inhibition, and administration in earlier-stage disease settings to improve clinical outcomes. Combination strategies integrating virus-based vaccines with radiation, hormonal therapy, and chemotherapy are being actively explored to enhance efficacy. While encouraging, further research and clinical trials are necessary to fully evaluate the therapeutic potential of virus-based vaccines in prostate cancer treatment.

3.5. Comparative Summary of Prostate Cancer Vaccine Types

Each prostate cancer vaccine type varies significantly in its clinical viability, with distinct strengths and limitations. Dendritic cell-based vaccines, like Sipuleucel-T, induce strong immune responses but are costly and difficult to scale due to their patient-specific production requirements. DNA and RNA vaccines offer a balance of scalability, cost-effectiveness, and immune activation, with mRNA vaccines showing great promise in personalized oncology. Peptide-based vaccines are simple and highly affordable, yet limited by their need for adjuvants and patient-specific HLA compatibility. Lastly, viral/vector-based vaccines provide robust immune responses, but preexisting immunity against viral vectors and moderate scalability issues pose challenges for long-term success.

While no single vaccine platform has demonstrated universal superiority, research efforts are increasingly focused on hybrid vaccine strategies and personalized immunotherapy approaches. One promising direction involves combining mRNA-based vaccines with ICIs to sustain T cell activation and counteract tumor-induced immunosuppression. Similarly, nanoparticle-based vaccine delivery systems are being explored to enhance antigen presentation and immune cell uptake while improving vaccine stability. Advances in AI-driven antigen selection are also transforming vaccine design by identifying highly immunogenic neoantigens, enabling patient-specific vaccine formulations with optimized immune activation.

4. Advances in Clinical Trials and Therapeutic Outcomes

4.1. Highlights from Recent Clinical Trials

The clinical development of prostate cancer vaccines has been shaped by numerous trials assessing their safety, immunogenicity, and efficacy in various patient populations. While many vaccines have demonstrated robust immune activation, translating these responses into meaningful survival benefits has proven challenging. To systematically evaluate trial outcomes, we assess key metrics: safety profile, immune response rates, overall and progression-free survival benefits, and patient selection criteria.

Across all the recent clinical trials, prostate cancer vaccines exhibited excellent safety profiles, with no dose-limiting toxicities reported. The 5T4 vaccine showed minimal adverse events, and patients tolerated the vaccine well in the phase I trial [125]. Similarly, the RhoC vaccine was well-tolerated in the phase I/II trial, with no grade 3 or higher adverse events recorded [126]. The PSA/MUC-1/brachyury vaccine demonstrated high tolerability in phase I trials, with no severe side effects observed, and patients experienced only mild, transient symptoms such as fatigue or localized injection site reactions [74]. PROSTVAC, tested in a phase III trial, also displayed an acceptable safety profile, with the most common adverse events being injection site reactions and mild fatigue [127]. Serious treatment-related events were rare across all trials. These findings underscore the feasibility of prostate cancer vaccines as a safe therapeutic approach.

Clinical trials assess vaccine-induced immune activation using a combination of T cell response assays (ELISPOT, flow cytometry, proliferation assays), tumor infiltration analysis (TIL assessment, IHC, RNA-seq), and cytotoxicity assays (granzyme B, perforin release, tumor lysis assays). The degree of immune activation varied significantly scross trials, reflecting differences in vaccine design, antigen selection, and immunological context. The 5T4 vaccine demonstrated robust T-cell activation, with both CD4+ and CD8+ responses and enhanced tumor infiltration, suggesting a highly immunogenic profile in early-stage prostate cancer [125]. Similarly, the PSA/MUC-1/brachyury vaccine induced broad antigen-specific immunity, with 47% of patients responding to all three tumor antigens, though the quality of these responses in controlling tumor progression remains uncertain [74]. The RhoC vaccine primarily activated CD4+ T cells, with only occasional CD8+ responses, raising concerns about its ability to mount effective cytotoxic T cell-mediated tumor clearance [126]. In stark contrast, PROSTVAC failed to induce a clinically meaningful immune response, with no significant increase in tumor-infiltrating lymphocytes (TILs) or durable T cell activity, which may have contributed to its lack of efficacy in phase III trials [62]. The variability in immune response rates suggests that certain vaccine strategies (such as multi-antigen targeting in PSA/MUC-1/brachyury and T-cell infiltration enhancement in 5T4 vaccine) may offer superior immunogenic potential compared to single-antigen or weakly immunostimulatory approaches.

For vaccines to be effective, they must not only generate robust peripheral immune responses but also facilitate T cell infiltration into tumors, maintain immune memory, and overcome immunosuppressive mechanisms to achieve durable clinical efficacy. While some vaccines exhibited promising immune activation, their ability to translate immune responses into survival benefits varied considerably. The 5T4 vaccine has not yet reached long-term survival analysis, but its promising immune profile in early-stage prostate cancer suggests potential for disease-free survival (DFS) benefits in later trials [125]. The RhoC vaccine, despite showing long-lasting CD4+ activation, has not yet demonstrated significant overall survival (OS) improvement, though its role in delaying tumor recurrence is being investigated [126]. The PSA/MUC-1/brachyury vaccine, despite inducing broad immune responses in mCRPC, has not shown conclusive survival benefits, possibly due to the late-stage patient population in the trial [74]. Most notably, PROSTVAC, despite promising phase II data, failed to improve OS or PFS in its pivotal phase III trial, leading to its discontinuation as a monotherapy approach [62]. This comparison underscores the fact that immune activation alone is insufficient; vaccines must elicit a response that directly impacts tumor control and patient survival, which may require combination strategies.

The stage of disease, prior treatments, and biomarker status played a significant role in determining the success or failure of prostate cancer vaccines across clinical trials. Patients with non-metastatic or early metastatic disease tend to have better vaccine responses because their immune systems are less compromised. mCRPC patients, by contrast, often have an exhausted T cell population that is difficult to reinvigorate. The 5T4 vaccine, tested in early-stage prostate cancer, demonstrated strong CD8+ and CD4+ activation with enhanced tumor infiltration, likely due to a more intact immune system and a less immunosuppressive tumor microenvironment (TME) [125]. In contrast, the PSA/MUC-1/brachyury and PROSTVAC trials, conducted in metastatic castration-resistant prostate cancer (mCRPC) patients, failed to show significant clinical benefits despite inducing

immune responses. These failures were likely due to chronic antigen exposure leading to T cell exhaustion, immunosuppressive cytokines, and a lack of tumor-infiltrating lymphocytes (TILs), which are well-documented features of late-stage prostate cancer [128–130]. Prior treatments also influenced vaccine outcomes. Patients enrolled in the mCRPC trials (PROSTVAC, PSA/MUC-1/brachyury, RhoC) had received androgen deprivation therapy (ADT), chemotherapy, or radiotherapy, which can induce lymphodepletion and impair immune responsiveness [74, 126, 127]. In contrast, the 5T4 vaccine trial, conducted in earlier-stage patients with minimal prior treatment, saw a more favorable immune response, reinforcing the importance of administering vaccines before significant immune system compromise [125].

Biomarker status plays a crucial role in determining which patients are most likely to benefit from prostate cancer vaccines, influencing both immune response consistency and overall clinical efficacy. The absence of predictive biomarkers in some trials led to inconsistent responses, while targeting more specific tumor-associated markers or neoantigens may improve vaccine effectiveness in future trials. In the PSA/MUC-1/brachyury vaccine trial, while 47% of patients exhibited immune responses to all three antigens, the lack of biomarker-driven patient selection resulted in heterogeneous outcomes, where some patients mounted strong immune responses, while others saw no clinical benefit [74, 126]. This suggests that without validated biomarkers to stratify patients, the immune system's ability to recognize and respond to vaccine-targeted antigens varies widely. In contrast, vaccines designed around tumor-specific fusion proteins or personalized neoantigens, such as TMPRSS2:ERG, may provide a more targeted approach by ensuring that the selected antigens are uniquely expressed in a patient's tumor, reducing the likelihood of immune escape.

4.2. Challenges in Clinical Trials

While prostate cancer vaccines have consistently demonstrated strong immunogenicity in clinical trials, their ability to translate immune activation into survival benefits remains limited, particularly in advanced disease settings. As discussed in Section 4.1, vaccines such as 5T4 and RhoC exhibited robust CD4+ and CD8+ T-cell responses, yet failed to achieve significant tumor control, suggesting that tumor heterogeneity and immune resistance posed major barriers to efficacy [125, 126]. Similarly, the PSA/MUC-1/brachyury vaccine, despite generating broad antigen-specific immune responses in 47% of patients, produced only modest clinical benefits in metastatic castration-resistant prostate cancer (mCRPC), where immune suppression is highly prevalent [74]. The PROSTVAC trial underscored these challenges, as its promising early-phase immunogenicity did not lead to improved overall survival (OS) in phase III, ultimately leading to its discontinuation [127]. The common trend observed across these trials suggests that while vaccine-induced T cells can be activated in peripheral circulation, they often fail to infiltrate tumors, persist within an immunosuppressive microenvironment, or effectively eliminate antigen-adaptive tumor cells.

This disconnection between immunogenicity and clinical efficacy stems from several key factors. First, poor tumor infiltration of vaccine-induced T cells significantly reduces the impact of immunization [131]. As seen in the PROSTVAC trial, despite evidence of peripheral immune activation, T cells failed to effectively migrate into tumor sites, likely due to low chemokine expression and stromal barriers that characterize prostate cancer's immune-cold microenvironment [132]. Second, the immunosuppressive tumor microenvironment (TME) neutralizes vaccine-induced T cells [133], as seen in trials such as PSA/MUC-1/brachyury and RhoC, where immune responses were evident but did not lead to durable tumor control. This suppression is mediated by high levels of TGF-β, IL-10, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs), which collectively inhibit T cell expansion and cytotoxic activity. Third, tumor antigen escape and heterogeneity further weaken vaccine efficacy, as prostate cancer cells downregulate or modify target antigens to evade immune detection [134, 15, 111]. While multi-antigen vaccines like PSA/MUC-1/brachyury attempted to address this issue, the lack of significant survival benefits suggests that tumor adaptation and antigen loss remain major challenges. Finally, vaccine-induced T cells frequently express exhaustion markers (PD-1, LAG-3, TIM-3), limiting their function within tumors. None of the clinical trials discussed in before incorporated ICIs such as anti-PD-1 or anti-CTLA-4, which could have prevented T cell exhaustion and sustained antitumor immunity [135, 136].

The failure of these vaccine trials in late-stage mCRPC patients further highlights the importance of patient selection and timing of immunotherapy. While the 5T4 vaccine was tested in early-stage prostate cancer and demonstrated promising immune activation, vaccines such as PROSTVAC and PSA/MUC-1/brachyury were evaluated in heavily pretreated mCRPC patients, where chronic antigen exposure and prior therapies had already compromised immune responsiveness [137]. This suggests that prostate cancer vaccines may be more effective when administered in earlier disease stages,

before the immune system is suppressed and the tumor microenvironment becomes hostile to immune activation

To bridge the gap between immunogenicity and clinical efficacy, future vaccine strategies must incorporate multiple synergistic approaches. Enhancing T cell infiltration into tumors through chemokine-modulating agents (CXCL9, CXCL10), oncolytic viruses, or radiotherapy could improve tumor targeting [138–142]. Expanding antigen targeting strategies by incorporating both shared prostate cancer and patient-specific neoantigens could further reduce tumor escape mechanisms. Furthermore, shifting vaccine administration to earlier-stage prostate cancer could enhance efficacy, preserve immune function, and maximize patient benefit [143]. The failure of PROSTVAC and other monotherapy vaccine trials underscores the necessity of combination immunotherapy approaches. Overcoming immune suppression within the TME by combining vaccines with ICIs, TGF-β inhibitors, or myeloid cell-targeting therapies may help sustain vaccine-induced responses. By integrating these advancements, future prostate cancer vaccines may overcome the current limitations and achieve durable clinical success.

5. Facilitating Factors and Barriers in Vaccine Development

5.1. Key Drivers of Success in Prostate Cancer Vaccine Development

The success of prostate cancer vaccine development is driven by a combination of scientific advancements, technological innovations, and strategic clinical and economic considerations. While clinical response and immunogenicity remain central to vaccine efficacy, manufacturing scalability, cost-effectiveness, and real-world applicability have emerged as equally critical metrics for determining long-term success. The availability of well-characterized TAAs such as PSA, PSMA, and PAP has provided specific and widely expressed immunotherapy targets, minimizing off-target effects and improving tumor-specific immune activation [144–146]. The success of Sipuleucel-T, the first FDA-approved therapeutic vaccine for metastatic castration-resistant prostate cancer (mCRPC), demonstrates the potential of leveraging tumor-specific antigens to generate antitumor T-cell responses [147].

Beyond antigen selection, immune costimulatory molecules have played a vital role in vaccine efficacy. Incorporating GM-CSF in Sipuleucel-T and ICAM-1 in PSA-Tricom has enhanced antigen presentation, amplified T-cell activation, and prolonged immune response durability [116, 148]. Additionally, early patient stratification has proven essential in vaccine success, as patients with low tumor burden and early-stage disease tend to exhibit stronger immune responsiveness and fewer complications from tumor-induced immune suppression [149]. This highlights the importance of matching vaccine therapies to the appropriate disease stage, ensuring optimal effectiveness and reducing the likelihood of treatment failure due to tumor-driven immune evasion. Advancements in RNA and DNA-based vaccine platforms have significantly improved manufacturing scalability and cost-effectiveness, making these therapies more feasible for widespread clinical application [150]. Unlike autologous cell-based vaccines (e.g., Sipuleucel-T), which require personalized ex vivo processing, synthetic RNA/DNA vaccines enable bulk manufacturing, allowing for faster, more affordable production without compromising immunogenicity. The use of lipid nanoparticle (LNP) delivery in mRNA vaccines and electroporation-enhanced DNA vaccines has further improved antigen stability and uptake, increasing their real-world applicability by streamlining storage, distribution, and administration logistics [91, 151].

Assessing the success of prostate cancer vaccines requires consideration beyond clinical response metrics, incorporating manufacturing feasibility, cost-effectiveness, and real-world applicability. A vaccine that demonstrates high efficacy but is too expensive to produce or distribute at scale may struggle to achieve widespread adoption. Likewise, if a vaccine requires specialized delivery systems or patient-specific modifications, its accessibility and real-world impact may be limited despite strong clinical data. By integrating scientifically validated antigen targets, scalable manufacturing platforms, cost-efficient production models, and streamlined distribution strategies, the next generation of prostate cancer vaccines can overcome existing barriers and achieve both clinical and commercial success.

5.2. Challenges in Prostate Cancer Vaccine Development: Tumor Heterogeneity, Immune Evasion, and Financial Constraints

As previously mentioned, Prostate cancer vaccine development faces critical challenges related to tumor heterogeneity, immune evasion mechanisms, and financial constraints, all of which impact clinical efficacy and commercial viability. Tumor heterogeneity, driven by diverse genetic profiles and biological behaviors, enables cancer cells to evade immune detection and resist targeted immunotherapy, making it difficult for vaccines to generate consistent and durable responses across patient populations [152]. Additionally, immune evasion strategies, such as upregulation of checkpoint proteins (PD-1/PD-L1) and the creation of an immunosuppressive

tumor microenvironment, significantly limit vaccine efficacy [54–58]. The presence of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and immunosuppressive cytokines (IL-10, TGF-β) further suppresses T-cell activation and antitumor immunity, explaining why some vaccine trials have failed to achieve significant survival benefits despite eliciting measurable immune responses [153–156].

Beyond biological barriers, financial constraints remain a major obstacle to vaccine development and accessibility. The commercial success of prostate cancer vaccines relies on the balance between manufacturing costs, pricing strategies, and demonstrated clinical benefits. High development and production costs must be justified by meaningful survival improvements, while pricing models determine market accessibility and adoption [157]. This interplay ultimately decides whether a vaccine achieves financial sustainability or faces limited clinical uptake, as seen with Sipuleucel-T, which, despite FDA approval, struggled commercially due to high costs and modest clinical benefits [158]. Prostate cancer vaccines, particularly cell-based therapies like Sipuleucel-T, involve labor-intensive manufacturing, requiring autologous dendritic cell extraction, ex vivo antigen priming, and reinfusion, increasing per-dose costs to over $90,000 per patient [159, 160]. Similarly, viral vector-based vaccines like PROSTVAC demand large-scale viral engineering and strict biosafety oversight, further escalating expenses.

Pricing strategies depend on clinical benefit and competition within the oncology market [157]. Sipuleucel-T's high cost was not justified by its modest 4.1-month OS increase, leading to low insurance reimbursement and market rejection, contributing to the manufacturer's eventual bankruptcy [158]. In contrast, ICIs such as nivolumab and pembrolizumab, despite being similarly expensive, gained widespread adoption due to durable responses and strong combination potential with other therapies [161, 162]. This highlights the importance of demonstrating sustained survival benefits and identifying ideal patient populations for premium pricing to be justifiable. The commercial viability of prostate cancer vaccines depends on their ability to generate significant clinical benefit that justifies their manufacturing costs and pricing structure. The failure of PROSTVAC's Phase III trial, despite strong early immune activation, exemplifies the disconnect between immunogenicity and survival benefit, leading to loss of investment and discontinuation [163].

While pricing strategies and production costs determine market accessibility, the ability to demonstrate meaningful survival benefits through well-defined clinical endpoints ultimately influences regulatory approval, physician adoption, and long-term viability of these therapies [164]. The osseous nature of prostate cancer metastases complicates radiographic assessments, leading to inconsistencies in evaluating true disease progression [165]. As a result, progression-free survival (PFS) is frequently used as a primary endpoint in prostate cancer immunotherapy trials, though its reliability varies significantly [166–168]. While radiographic PFS (rPFS) and clinical PFS (cPFS) have been proposed as surrogate endpoints for overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC), their validity remains under investigation. Supporting this, a meta-analysis of nine randomized trials found surrogate threshold effects of 0.80 for rPFS and 0.81 for cPFS, indicating their potential to streamline phase III trials by accelerating data collection and expediting regulatory approvals [169]. However, given the disconnect between immune response generation and long-term survival benefits, future vaccine trials must integrate alternative clinical endpoints, such as biomarker-driven response measures and immune-related survival metrics, to better capture treatment efficacy. Despite these challenges, the advancement of prostate cancer vaccines will depend on overcoming tumor-driven immune resistance, refining patient stratification, improving clinical endpoints, and addressing financial sustainability.

5.3. Innovative Strategies to Address Challenges in Prostate Cancer Vaccine Development.

To overcome the persistent challenges in prostate cancer vaccine development, recent studies are adopting multi-faceted strategies that enhance immune activation, improve scalability, and optimize patient selection. One of the most promising approaches is the combination of vaccines with ICIs, such as anti-PD-1/PD-L1 or anti-CTLA-4 antibodies, to counteract tumor-induced immunosuppression. While ICIs alone have shown limited efficacy in prostate cancer, their combination with vaccines has demonstrated synergistic effects in preclinical and early-phase trials, boosting tumor-specific T-cell recruitment and effector function [170, 171]. Additionally, neoantigen-targeting vaccines, which leverage tumor-specific mutations to enhance immune responses, are particularly beneficial for patients with high tumor burden or aggressive disease, where immune escape is more common [172, 173]. Vaccine designs are also evolving to target multiple TAAs or induce epitope spreading, ensuring a broader immune response that reduces the risk of tumor antigen loss and immune evasion [174, 175]. Advances in synthetic vaccine manufacturing, such as DNA and RNA-based platforms, provide cost-effective, scalable solutions that maintain high immunogenicity while reducing production

complexity [176]. Moreover, refocusing clinical trials on patients with early-stage disease or minimal tumor burden has shown greater immunotherapy efficacy, as these patients have less immune dysfunction and lower levels of tumor-induced suppression [149]. The integration of biomarker-driven monitoring and adaptive trial designs further enables real-time assessment of immune responses, allowing for personalized treatment adjustments that optimize patient outcomes [177, 178].

The integration of artificial intelligence (AI) into prostate cancer vaccine development is addressing critical barriers that have historically slowed progress in immunotherapy. AI-driven tools are revolutionizing epitope selection, optimizing antigen delivery, accelerating adjuvant discovery, and personalizing vaccine formulations, enabling faster and more precise vaccine design [78]. As highlighted earlier, one of the primary challenges in prostate cancer vaccine development is tumor heterogeneity and antigen escape, where cancer cells modify or downregulate their antigens to evade immune detection. AI is helping to overcome this issue by analyzing vast genomic, transcriptomic, and proteomic datasets to identify highly stable, immunogenic epitopes that remain consistently expressed across different tumor subtypes [179, 180]. Through machine learning models, AI can differentiate between shared prostate cancer antigens (e.g., PSMA, PAP, TMPRSS2:ERG) and patient-specific neoantigens, allowing for the development of mutation-specific vaccines that minimize the risk of immune evasion and improve long-term efficacy [181].

Beyond epitope selection, AI is also optimizing vaccine formulations and delivery systems, addressing the inefficiencies of traditional platforms that often result in suboptimal antigen expression and weak immune responses. Deep learning algorithms can refine mRNA and DNA vaccine sequences, predicting the most effective codon usage, structural stability, and antigen expression efficiency to enhance antigen presentation and T-cell activation [182]. This is particularly useful for mRNA vaccines, where AI-assisted optimization of untranslated regions (UTRs) and lipid nanoparticle (LNP) formulations improves stability, cellular uptake, and protein translation efficiency [183, 184]. Similarly, AI-driven modeling of electroporation parameters in DNA vaccines ensures that antigen uptake is maximized, boosting immune response strength and durability [185]. In addition to antigen design, AI is transforming adjuvant discovery, a key component in ensuring vaccine efficacy [186]. Many prostate cancer vaccines have struggled to induce strong, sustained immune responses, necessitating the use of adjuvants that enhance dendritic cell activation, cytokine production, and T-cell priming. AI-driven screening of large biochemical and pharmacological databases enables the rapid identification of novel immune-stimulatory molecules, predicting synergistic interactions between adjuvants and antigens. This approach not only accelerates adjuvant discovery but also ensures that the selected adjuvants enhance vaccine efficacy while minimizing toxicity, an issue that has limited previous vaccine formulations [186, 187].

AI could also play a crucial role in personalizing prostate cancer vaccines and refining patient selection strategies. Given the significant genetic variability, immune status differences, and tumor burden heterogeneity among patients, one-size-fits-all vaccines are often ineffective. AI-driven models predict patient-specific immune responses, enabling the development of personalized vaccine formulations tailored to an individual's tumor profile and immune landscape [181]. Furthermore, AI-based analysis of biomarkers such as PD-L1 expression, tumor mutational burden, and T-cell infiltration levels allows for real-time patient stratification, ensuring that vaccines are administered to patients most likely to benefit, thereby increasing clinical trial success rates and regulatory approval likelihood [78]. Despite its vast potential, AI-driven vaccine development faces several key challenges that must be addressed to ensure clinical translation. Tumor heterogeneity and genetic variability introduce complexities that require large, high-quality datasets to improve AI prediction accuracy [188]. Additionally, concerns regarding data privacy and potential biases in AI algorithms must be carefully managed to ensure equity in vaccine development and access [189]. Collaboration between oncologists, immunologists, computational biologists, and AI specialists is essential to bridge the gap between AI-based discoveries and clinical applications [190]. Furthermore, establishing careful navigation of a complex regulatory landscape will be necessary to guarantee that AI-assisted vaccine development meets safety, efficacy, and accessibility standards, accelerating its transition from computational modeling to real-world implementation [191].

By leveraging AI for precision epitope design, antigen optimization, and real-time immune response monitoring, prostate cancer vaccines have the potential to become more effective, adaptable, and widely accessible. As AI continues to refine vaccine design and improve clinical predictability, its integration into cancer immunotherapy may redefine the future of prostate



Figure 3. Overcoming the prostate cancer tumor microenvironment. Prostate cancer cells express PD-L1 to suppress cytotoxic T cells, but immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) block this pathway. Reactivated T cells then release cytotoxic molecules (perforin and granzymes), inducing tumor cell death.

cancer treatment, overcoming challenges that have historically hindered vaccine development.

6. Integrating Vaccines with Complementary Therapeutic Modalities

Prostate cancer vaccine combination therapies are gaining momentum as a promising strategy to overcome immune resistance and enhance treatment efficacy. By integrating vaccines with checkpoint inhibitors, hormone therapy, chemotherapy, radiotherapy, and emerging targeted therapies, researchers aim to exploit synergistic mechanisms that improve immune activation, tumor clearance, and treatment durability [192]. As stated previously, while cancer vaccines alone can stimulate tumor-specific T-cell responses, their effectiveness is often limited by immunosuppressive mechanisms in the tumor microenvironment (TME). Combination approaches aim to sustain and amplify vaccine-induced immune responses, making them more effective in generating durable antitumor immunity [193].

Figure 3 highlights the interplay between tumor cells and the immune system within the prostate cancer microenvironment, as well as how immunotherapies can overcome immunosuppressive barriers. Prostate cancer cells release signals that attract and modulate immune cells. Activated $CD8^+$ T cells approach the tumor, but their cytotoxic activity can be suppressed when the tumor cell expresses immune checkpoint molecules like PD-L1, which binds to PD-1 on T cells. This interaction dampens T cell function, allowing the tumor to evade destruction. The right side of the figure illustrates how immune checkpoint inhibitors—such as anti-PD-1 or anti-PD-L1 antibodies—can block this inhibitory pathway, restoring T cell activation. Once reactivated, T cells secrete cytotoxic molecules (e.g., perforin and granzymes), ultimately inducing tumor cell death. By interrupting the tumor's immune evasion tactics, these therapies enhance the effectiveness of the immune response against prostate cancer cells.

6.1. Strategic Sequencing of Vaccine Administration in Combination Therapies

The timing of vaccine administration in relation to other therapies plays a critical role in determining clinical outcomes. In immune checkpoint inhibitor combinations, vaccines should ideally be administered before or concurrently with ICIs, as they prime the immune system by generating tumor-specific T cells, while ICIs sustain T-cell activity and prevent exhaustion [194, 195]. The phase I trial of PROSTVAC with ipilimumab (anti-CTLA-4) and GM-CSF supports this sequencing, showing prolonged overall survival (31.6 months) compared to PROSTVAC alone (25.1 months), with a significant proportion of patients achieving PSA declines greater than 50% [173, 196, 197]. Similarly, vaccines administered before anti-PD-1 therapy (e.g., nivolumab or pembrolizumab) may enhance checkpoint blockade efficacy, as seen in preliminary responses demonstrating tumor volume reduction and durable PSA declines [198].

For hormone therapy combinations, evidence suggests that administering vaccines before androgen deprivation therapy (ADT) optimizes immune responses. The STAND trial, which combined Sipuleucel-T with ADT, showed more robust and sustained T-cell activation when the

vaccine was given prior to ADT, with immune responses lasting up to 24 months [199]. This may be due to ADT-induced antigen release and increased T-cell infiltration, which synergizes with vaccine-induced immune priming. Similarly, combining Sipuleucel-T with abiraterone acetate (AA) and prednisone in mCRPC patients demonstrated safety and feasibility, with no loss of vaccine potency despite concurrent ADT [200]. In chemotherapy-based combinations, sequencing also plays a role. Dendritic cell-based immunotherapy (DCVAC/PCa) combined with docetaxel chemotherapy initially showed prolonged survival and induction of PSA-specific T cells in early-phase trials [201]. However, the large-scale VIABLE Phase III trial failed to achieve significant overall survival benefits [202]. Despite this, DCVAC/PCa maintained a favorable safety profile, reinforcing its potential as part of a rationally timed combination strategy [202, 203]. Given that chemotherapy can enhance antigen presentation by inducing immunogenic cell death, further trials are needed to refine optimal dosing and sequencing to avoid excessive immune suppression [204, 205]. For radiotherapy (RT) combinations, vaccines are best administered following RT, leveraging RT-induced immunogenic cell death and TME remodeling. Radiation therapy can function as an in-situ vaccine, exposing tumor antigens and promoting an inflamed, immunostimulatory environment that enhances vaccine efficacy [206, 207]. This synergy has been demonstrated across various cancer types, including prostate cancer and HPV-associated head and neck cancers [208, 209]. RT enhances antigen-specific CD8+ T-cell infiltration, which is crucial for vaccine-driven immune responses [209]. Photodynamic therapy (PDT) combined with vaccine administration post-RT demonstrated a 50% tumor cure rate in preclinical models, further highlighting the importance of treatment sequencing [210].

6.2. Economic and Logistical Challenges of Multi-Modal Therapies

While combination therapies hold great promise in enhancing prostate cancer vaccine efficacy, the financial burden and logistical complexity of integrating multiple high-cost treatments remain significant barriers to widespread adoption. The addition of ICIs, hormone therapy, chemotherapy, and radiotherapy to vaccine regimens significantly increases treatment costs, raising concerns about cost-effectiveness, reimbursement feasibility, and patient accessibility. These challenges mirror the financial constraints discussed in Section 5.2, where high manufacturing costs, premium pricing models, and uncertain long-term benefits have limited the adoption of monotherapy like Sipuleucel-T. With combination therapies, these issues are further compounded by the need for multiple concurrent or sequential treatments, making financial sustainability a major concern for healthcare systems and patients alike. Sipuleucel-T alone costs approximately $90,000 per patient, while ICIs such as nivolumab or pembrolizumab range from $100,000 to $150,000 annually [159–162]. When combined, these therapies can exceed $200,000 per patient per year, making them financially inaccessible to many patients and healthcare systems. Adding expenses from radiotherapy and targeted agents (e.g., PARP inhibitors, enzalutamide) makes insurers and healthcare providers reluctant to approve or reimburse these regimens without clear survival benefits [211]. Furthermore, as noted earlier, prostate cancer vaccines have yet to demonstrate long-term benefits, making it hard to justify their premium pricing in combination therapies.

Beyond direct treatment costs, logistical challenges also limit the scalability of combination therapies. Personalized cell-based vaccines (e.g., Sipuleucel-T) require individualized ex vivo processing, creating supply chain and distribution hurdles that are further complicated when combined with rigid dosing schedules for ICIs or chemotherapy [212]. The need for coordinated treatment administration across different oncology specialties adds another layer of complexity, increasing hospital resource utilization and placing additional burdens on healthcare infrastructure [190]. For example, radiotherapy combined with vaccines requires precise sequencing to ensure optimal immune stimulation, necessitating frequent clinical visits and specialized facilities that may not be available in all treatment centers.

To address these financial and logistical barriers, several strategies must be considered. First, implementing biomarker-driven patient stratification can ensure that only patients most likely to benefit receive high-cost combination treatments, improving cost-effectiveness [177, 178]. Second, adopting outcome-based pricing models, where manufacturers receive reimbursement only if the therapy meets predefined clinical benchmarks (e.g., prolonged overall survival or PSA reduction), could help balance innovation with financial sustainability [213, 214]. Third, prioritizing scalable, cost-efficient vaccine platforms like RNA/DNA-based vaccines may enable broader accessibility by reducing manufacturing and distribution costs, a challenge that has historically limited cell-based immunotherapies like Sipuleucel-T. Ultimately, while combining prostate cancer vaccines with ICIs, chemotherapy, radiotherapy, and targeted agents presents a scientifically sound approach, ensuring

economic feasibility and practical implementation will be crucial for real-world adoption. Development of prostate cancer vaccine combination therapy must continue refining cost-benefit analyses, optimizing treatment sequencing, and exploring innovative pricing structures to balance clinical impact with affordability, ensuring that these advances benefit a broader patient population holistically.

6.3. Biological Synergies Underpinning Combination Therapies

Each combination therapy exploits distinct molecular mechanisms to enhance tumor targeting and immune activation. Vaccines alone generate tumor-specific T-cell responses, but their activity is often dampened by immune checkpoints and suppressive factors in the TME. The addition of ICIs blocks these inhibitory pathways, ensuring that vaccine-induced T cells remain active and capable of infiltrating tumors. This synergy is evident in PROSTVAC with ipilimumab, where checkpoint inhibition amplified vaccine-driven immune responses, leading to better tumor control [197].

Hormone therapy combinations, particularly the combination of ADT and vaccines, function by modulating antigen expression and immune accessibility [215]. Androgen receptor (AR) signaling suppresses MHC class I expression, reduces T-cell infiltration, and contributing to CD8+ T cell exhaustion, ultimately limiting vaccine efficacy [216]. ADT reverses these effects, increasing tumor antigen presentation and immune cell recruitment, thereby enhancing vaccine-driven responses [217, 218]. This explains why Sipuleucel-T followed by ADT in the STAND trial showed prolonged immune responses compared to ADT alone [199]. In chemotherapy-based combinations, agents like mitoxantrone induce immunogenic cell death, which releases tumor antigens and enhances dendritic cell activation [204, 205]. This creates an optimal environment for vaccine priming, as seen in early trials with DCVAC/PCa [201]. However, excessive chemotherapy can lead to lymphodepletion, necessitating precise dosing to avoid impairing vaccine-induced immunity [201, 202]. Combination with radiotherapy, also leverage the ability to promote immunogenic cell death, upregulate TAAs, and disrupt the suppressive tumor stroma. This creates a favorable immune microenvironment, enhancing vaccine efficacy [206, 207]. RT also induces vascular remodeling, improving immune cell infiltration into tumors, which is critical for long-term immune surveillance and durable responses [206, 207].

7. Emerging Horizons and Innovations in Prostate Cancer Vaccine Research.

7.1. Emerging Vaccine Platforms: Advancing Toward Clinical Integration

The future of prostate cancer vaccines is bright, driven by breakthroughs in immunology, molecular biology, and cutting-edge technologies. The trajectory of prostate cancer vaccine development is shaped by ongoing clinical advancements, manufacturing feasibility, and regulatory progress. The transition from experimental platforms to standard-of-care therapies follows a multi-phase evolution, with some strategies approaching short-term clinical translation, while others remain in long-term research and optimization before widespread implementation. Vaccines currently undergoing Phase I/II trials and nearing Phase III validation are the closest to clinical adoption. Among these, RNA-based vaccines are showing the strongest potential for early regulatory approval due to their rapid production, demonstrated immunogenicity in other cancers, and ongoing improvements in antigen delivery systems. While mRNA platforms face challenges in stability and antigen presentation in solid tumors, the application of lipid nanoparticle (LNP) carriers and self-amplifying RNA (saRNA) modifications is addressing these limitations [91, 151, 183]. Given that regulatory agencies have already established accelerated pathways for mRNA vaccine approvals, these innovations are expected to transition into prostate cancer treatment strategies following confirmatory trials in the next few development cycles [219]. Similarly, DNA-based vaccines, which offer greater stability and lower production costs, are positioned for mid-to-late-stage trials [220]. Although historically hindered by weak immunogenicity, advancements in electroporation-based delivery, optimized plasmid constructs, and integrated adjuvants are showing promising improvements in T-cell activation [221, 222]. If ongoing trials confirm longer-lasting immune responses, DNA vaccines will likely be integrated into treatment regimens soon after regulatory validation in the next phase of immunotherapy adoption.

As vaccine platforms mature, the next stage of implementation will involve combining vaccines with other immunotherapies, particularly ICIs, androgen deprivation therapy (ADT), and radiotherapy. Checkpoint inhibitor combinations, such as PROSTVAC + ipilimumab (anti-CTLA-4) and vaccine + nivolumab (anti-PD-1), have already demonstrated synergistic immune effects in early-phase trials [197, 223]. While toxicity management and treatment sequencing remain areas of optimization, checkpoint blockade is expected to become a key enhancer of vaccine efficacy, particularly in patients with

T-cell-excluded tumors that require immune modulation [197]. Similarly, vaccine combinations with radiotherapy and hormonal therapy are gaining traction, as radiotherapy can function as an in-situ vaccine by increasing tumor antigen release and immune visibility [206, 207]. The Sipuleucel-T + ADT (STAND trial) has already shown long-term immune memory effects, confirming that hormonal therapy primes the tumor microenvironment for enhanced vaccine responses [199]. Ongoing trials will refine optimal sequencing strategies, patient stratification models, and durability of immune protection, ensuring that these combinations are effectively positioned as mainstream therapeutic regimens in the next phase of clinical expansion. While oncolytic virus (OV)-based vaccines remain in the transition phase between early and mid-term trials, their ability to selectively infect tumors, induce direct cell lysis, and stimulate antitumor immunity positions them as a future adjunct to checkpoint blockade and radiation-based strategies [224–226]. Challenges such as pre-existing antiviral immunity and inefficient viral persistence in solid tumors are being addressed through next-generation viral vector engineering and combination therapy formulations [119, 123, 124], setting the stage for future mid-term clinical applications.

The emergence of neoantigen-based personalized cancer vaccines represents a transformative shift toward individualized immunotherapy [227]. By leveraging patient-specific tumor mutations, these vaccines provide precision-targeted immune responses, reducing immune tolerance and off-target effects [228]. However, their implementation faces major scalability challenges, as each vaccine must be custom-manufactured per patient, significantly increasing production time and costs. AI-driven tumor profiling and batch-processing models are helping accelerate neoantigen selection [229–231], allowing for semi-personalized vaccine production, where patients are stratified into mutation clusters rather than requiring fully individualized vaccines. As these models undergo further refinement and regulatory adaptation, personalized vaccines are expected to move from experimental trials into select patient applications as an advanced-stage immunotherapy option [229]. Another key area of long-term research involves improving vaccine accessibility through automation and cost-efficient scaling models. The development of automated AI-driven vaccine synthesis platforms could eventually allow for real-time customization of immunotherapies based on evolving tumor profiles, further advancing adaptive precision oncology.

7.2. Technological Limitations and Advances in Prostate Cancer Vaccine Development

The integration of artificial intelligence (AI) and machine learning (ML) models into prostate cancer vaccine development has accelerated neoantigen discovery, optimized vaccine design, and improved immune response predictions. However, for AI-generated vaccine candidates to be clinically validated, they must undergo rigorous experimental and clinical testing to ensure accuracy, safety, and efficacy [191]. One of the biggest challenges is demonstrating that AI-selected antigens elicit strong, durable immune responses in human trials, as preclinical models may not fully capture the complexity of human immune interactions [78]. Validation requires retrospective testing against existing patient data, prospective clinical trials, and comparisons with conventional vaccine design methods to ensure that AI-driven predictions consistently improve patient outcomes. While early-stage trials for AI-driven cancer vaccines are underway in melanoma and lung cancer, prostate cancer applications remain in exploratory phases, awaiting regulatory confidence in AI's predictive reliability [229, 232, 233].

Beyond clinical validation, regulatory and ethical challenges pose significant barriers to the widespread adoption of AI-assisted immunotherapy [191]. Traditional fixed vaccine approval pathways struggle to accommodate continuously evolving AI-driven vaccine formulations, requiring new regulatory guidelines for real-time modifications. Transparency is another major concern, as many AI models function as black-box systems, making it difficult for researchers and regulators to interpret why certain tumor antigens are prioritized [234]. Ensuring explainability and independent validation of AI-generated decisions will be critical for regulatory acceptance. Furthermore, AI-driven vaccine development relies on large-scale genomic datasets, raising concerns about data privacy, informed consent, and equitable access to treatment [234]. If training data lacks diversity, AI models may introduce biases, leading to vaccines that are less effective for underrepresented patient populations. Ethical safeguards must be in place to protect patient data, prevent discriminatory outcomes, and ensure cost-effective accessibility [78, 234].

To successfully integrate AI-driven vaccine platforms into clinical practice, the industry must establish standardized validation frameworks, clear regulatory pathways, and robust ethical oversight. Researchers must ensure that AI models are explainable, reproducible, and free of bias, while regulatory bodies must evolve to accommodate adaptive vaccine formulations and automated antigen selection. Addressing these challenges will be crucial in

ensuring that AI-powered prostate cancer vaccines transition from experimental innovation to widely accessible immunotherapy, making precision cancer treatment both effective and equitable.

8. Conclusion

The development of prostate cancer vaccines represents a transformative leap in oncology, leveraging immunotherapy to target tumor-associated antigens (PSA, PSMA, PAP) through dendritic cell, DNA/RNA, peptide, and viral vector-based platforms. While these vaccines demonstrate safety and immunogenicity, clinical efficacy remains limited by tumor heterogeneity and immune evasion. Combining vaccines with immune checkpoint inhibitors (ICIs), radiotherapy, and androgen deprivation therapy (ADT) has shown synergistic potential, enhancing immune activation and tumor antigen release.

The most promising short-term strategy is the combination of prostate cancer vaccines with ICIs, which has demonstrated synergistic effects in early-phase trials by sustaining T-cell activation and preventing immune exhaustion. Vaccine combinations with radiotherapy and androgen deprivation therapy (ADT) are also emerging as effective approaches, enhancing immune priming and tumor antigen release. Among vaccine platforms, RNA-based vaccines hold the greatest potential for rapid clinical translation due to their scalability, cost-effectiveness, and ability to encode multiple neoantigens. Future research should prioritize optimizing RNA vaccine delivery systems and refining combination therapy protocols to maximize clinical efficacy and accessibility. In the short term, priority should be given to advancing vaccine + ICI combinations into Phase II/III trials, optimizing mRNA and DNA vaccine delivery, and refining biomarker-driven patient selection to enhance treatment efficacy. Efforts should also focus on cost reduction strategies, such as automated vaccine synthesis and modular RNA production, to improve accessibility. In the long term, the goal is to develop AI-driven adaptive vaccine platforms for real-time personalization, integrate prostate cancer vaccines into multi-modal treatment regimens, and establish new regulatory frameworks for continuously evolving immunotherapies. Achieving these milestones will transform prostate cancer vaccines from experimental therapies into widely available precision treatments.

Despite of all the advancements, several barriers must be addressed before prostate cancer vaccines become a standard component of clinical care. The most critical practical challenge is ensuring that these therapies are cost-effective and scalable. RNA and DNA vaccines, unlike dendritic cell-based therapies, allow for centralized, automated production, making them better suited for large-scale manufacturing. However, ensuring affordable pricing and equitable distribution will require strategic collaborations between pharmaceutical companies, healthcare systems, and regulatory agencies to implement better pricing models, such as outcome-based pricing, where reimbursement is contingent on clinical effectiveness. Vaccine trials should shift toward earlier-stage prostate cancer, where intervention may yield better outcomes, supported by biomarker-driven patient stratification. Moreover, integrating AI-driven immunotherapy models can further optimize patient selection, reduce trial costs, and accelerate clinical translation, ultimately transforming prostate cancer vaccines into widely accessible precision treatments.

Author Contributions: Conceptualization, T.E.T. and S.V.B.E.R.; methodology, T.E.T.; software, S.V.B.E.R.; validation, T.E.T.; formal analysis, S.V.B.E.R.; investigation, T.E.T. and S.V.B.E.R.; resources, T.E.T.; data curation, T.E.T. and S.V.B.E.R.; writing—original draft preparation, T.E.T. and S.V.B.E.R.; writing—review and editing, T.E.T. and S.V.B.E.R.; supervision, T.E.T. and G.L.A.T.; project administration, T.E.T.; funding acquisition, T.E.T. All authors have read and agreed to the published version of the manuscript.

Funding: This study does not receive external funding.

Data Availability Statement: Data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments: The authors would also like to thank the author's team for their contributions in data collection and administrative support that helped the study run smoothly.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., and Jemal, A. (2024). Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, *CA: A Cancer Journal for Clinicians*, Vol. 74, No. 3, 229–263. doi:10.3322/caac.21834.
2. Siegel, R. L., Miller, K. D., and Jemal, A. (2020). Cancer Statistics, 2020, *CA: A Cancer Journal for Clinicians*, Vol. 70, No. 1, 7–30. doi:10.3322/caac.21590.
3. Mattiuzzi, C., and Lippi, G. (2019). Current Cancer Epidemiology:, *Journal of Epidemiology and Global Health*, Vol. 9, No. 4, 217. doi:10.2991/jegh.k.191008.001.
4. Zlotta, A. R., Egawa, S., Pushkar, D., Govorov, A., Kimura, T., Kido, M., Takahashi, H., Kuk, C., Kovylina, M., Aldaoud, N., Fleshner, N., Finelli, A., Klotz, L., Sykes, J., Lockwood, G., and van der Kwast, T. H. (2013). Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men, *Journal of the National Cancer Institute*, Vol. 105, No. 14, 1050–1058. doi:10.1093/jnci/djt151.
5. Pernar, C. H., Ebot, E. M., Wilson, K. M., and Mucci, L. A. (2018). The Epidemiology of Prostate Cancer, *Cold Spring Harbor Perspectives in Medicine*, Vol. 8, No. 12, a030361. doi:10.1101/cshperspect.a030361.

6. Zhang, W., Cao, G., Wu, F., Wang, Y., Liu, Z., Hu, H., and Xu, K. (2023). Global Burden of Prostate Cancer and Association with Socioeconomic Status, 1990–2019: A Systematic Analysis from the Global Burden of Disease Study, *Journal of Epidemiology and Global Health*, Vol. 13, No. 3, 407–421. doi:10.1007/s44197-023-00103-6.
7. Taylor, L. G., Canfield, S. E., and Du, X. L. (2009). Review of Major Adverse Effects of Androgen-deprivation Therapy in Men with Prostate Cancer, *Cancer*, Vol. 115, No. 11, 2388–2399. doi:10.1002/cncr.24283.
8. Nagireddy, S., Qureshi, R., Best, J., Frech, F. S., Shah, K., Soni, Y., Kuchakulla, M., Narasimman, M., and Arora, H. (2021). Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer, A. Birbrair (Ed.), *Tumor Microenvironment* (Vol. 1329), Springer International Publishing, Cham, 295–323. doi:10.1007/978-3-030-73119-9_16.
9. Karantanos, T., Corn, P. G., and Thompson, T. C. (2013). Prostate Cancer Progression after Androgen Deprivation Therapy: Mechanisms of Castrate Resistance and Novel Therapeutic Approaches, *Oncogene*, Vol. 32, No. 49, 5501–5511. doi:10.1038/onc.2013.206.
10. Challa, A. A., Calaway, A. C., Cullen, J., Garcia, J., Desai, N., Weintraub, N. L., Deswal, A., Kutty, S., Vallakati, A., Addison, D., Baliga, R., Campbell, C. M., and Guha, A. (2021). Cardiovascular Toxicities of Androgen Deprivation Therapy, *Current Treatment Options in Oncology*, Vol. 22, No. 6, 47. doi:10.1007/s11864-021-00846-z.
11. Bagrodia, A., DiBlasio, C. J., Wake, R. W., and Derweesh, I. H. (2009). Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer: Current Management Issues, *Indian Journal of Urology : IJU : Journal of the Urological Society of India*, Vol. 25, No. 2, 169–176. doi:10.4103/0970-1591.52907.
12. Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D'Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., and Smith, M. R. (2015). Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them, *European Urology*, Vol. 67, No. 5, 825–836. doi:10.1016/j.eururo.2014.07.010.
13. Belli, C., Trapani, D., Viale, G., D'Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., and Curigliano, G. (2018). Targeting the Microenvironment in Solid Tumors, *Cancer Treatment Reviews*, Vol. 65, 22–32. doi:10.1016/j.ctrv.2018.02.004.
14. Li, D., Xu, W., Chang, Y., Xiao, Y., He, Y., and Ren, S. (2023). Advances in Landscape and Related Therapeutic Targets of the Prostate Tumor Microenvironment, *Acta Biochimica et Biophysica Sinica*, Vol. 55, No. 6, 956–973. doi:10.3724/abbs.2023092.
15. Ge, R., Wang, Z., and Cheng, L. (2022). Tumor Microenvironment Heterogeneity an Important Mediator of Prostate Cancer Progression and Therapeutic Resistance, *Npj Precision Oncology*, Vol. 6, No. 1, 1–8. doi:10.1038/s41698-022-00272-w.
16. Wu, J., Ji, H., Li, T., Guo, H., Xu, H., Zhu, J., Tian, J., Gao, M., Wang, X., and Zhang, A. (2024). Targeting the Prostate Tumor Microenvironment by Plant-Derived Natural Products, *Cellular Signalling*, Vol. 115, 111011. doi:10.1016/j.cellsig.2023.111011.
17. Rosenberg, S. A. (2014). IL-2: The First Effective Immunotherapy for Human Cancer, *The Journal of Immunology*, Vol. 192, No. 12, 5451–5458. doi:10.4049/jimmunol.1490019.
18. Riley, R. S., June, C. H., Langer, R., and Mitchell, M. J. (2019). Delivery Technologies for Cancer Immunotherapy, *Nature Reviews Drug Discovery*, Vol. 18, No. 3, 175–196. doi:10.1038/s41573-018-0006-z.
19. Kciuk, M., Yahya, E. B., Mohamed Ibrahim Mohamed, M., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., and Allaq, A. A. (2023). Recent Advances in Molecular Mechanisms of Cancer Immunotherapy, *Cancers*, Vol. 15, No. 10, 2721. doi:10.3390/cancers15102721.
20. Kaczmarek, M., Poznańska, J., Fechner, F., Michalska, N., Paszkowska, S., Napierała, A., and Mackiewicz, A. (2023). Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review, *Cells*, Vol. 12, No. 17, 2159. doi:10.3390/cells12172159.
21. Donninger, H., Li, C., Eaton, J. W., and Yaddanapudi, K. (2021). Cancer Vaccines: Promising Therapeutics or an Unattainable Dream, *Vaccines*, Vol. 9, No. 6, 668. doi:10.3390/vaccines9060668.
22. Kong, H. Y., and Byun, J. (2013). Emerging Roles of Human Prostatic Acid Phosphatase, *Biomolecules & Therapeutics*, Vol. 21, No. 1, 10–20. doi:10.4062/biomolther.2012.095.
23. Kissick, H. T., Sanda, M. G., Dunn, L. K., and Arredouani, M. S. (2013). Development of a Peptide-Based Vaccine Targeting TMPRSS2:ERG Fusion-Positive Prostate Cancer, *Cancer Immunology, Immunotherapy*, Vol. 62, No. 12, 1831–1840. doi:10.1007/s00262-013-1482-y.
24. Stultz, J., and Fong, L. (2021). How to Turn up the Heat on the Cold Immune Microenvironment of Metastatic Prostate Cancer, *Prostate Cancer and Prostatic Diseases*, Vol. 24, No. 3, 697–717. doi:10.1038/s41391-021-00340-5.
25. Qi, Y., Zhang, L., Liu, Y., Li, Y., Liu, Y., and Zhang, Z. (2024). Targeted Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Implications for Cancer Therapy, *Biomedicine & Pharmacotherapy*, Vol. 180, 117590. doi:10.1016/j.biopha.2024.117590.
26. Murray, T. B. J. (2021). The Pathogenesis of Prostate Cancer, *Prostate Cancer [Internet]*, Exon Publications. doi:10.36255/exonpublications.prostatecancer.pathogenesis.2021.
27. Huang, L., LaBonte, M. J., Craig, S. G., Finn, S. P., and Allott, E. H. (2022). Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention, *Cancers*, Vol. 14, No. 6, 1367. doi:10.3390/cancers14061367.
28. Grivennikov, S. I., Greten, F. R., and Karin, M. (2010). Immunity, Inflammation, and Cancer, *Cell*, Vol. 140, No. 6, 883–899. doi:10.1016/j.cell.2010.01.025.
29. Lin, M., Sun, X., and Lv, L. (2023). New Insights and Options into the Mechanisms and Effects of Combined Targeted Therapy and Immunotherapy in Prostate Cancer, *Molecular Therapy Oncolytics*, Vol. 29, 91–106. doi:10.1016/j.omto.2023.04.007.
30. de Bono, J. S., Guo, C., Gurel, B., De Marzo, A. M., Sfanos, K. S., Mani, R. S., Gil, J., Drake, C. G., and Alimonti, A. (2020). Prostate Carcinogenesis: Inflammatory Storms, *Nature Reviews Cancer*, Vol. 20, No. 8, 455–469. doi:10.1038/s41568-020-0267-9.
31. Sacdalan, D. B., and Lucero, J. A. (2021). The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development, *OncoTargets and Therapy*, Vol. 14, 2053–2064. doi:10.2147/OTT.S278089.
32. Nigam, M., Mishra, A. P., Deb, V. K., Dimri, D. B., Tiwari, V., Bungau, S. G., Bungau, A. F., and Radu, A.-F. (2023). Evaluation of the Association of Chronic Inflammation and Cancer: Insights and Implications, *Biomedicine & Pharmacotherapy*, Vol. 164, 115015. doi:10.1016/j.biopha.2023.115015.
33. Wang, D., and DuBois, R. N. (2015). Immunosuppression Associated with Chronic Inflammation in the Tumor Microenvironment, *Carcinogenesis*, Vol. 36, No. 10, 1085–1093. doi:10.1093/carcin/bgv123.
34. Lu, H., Ouyang, W., and Huang, C. (2006). Inflammation, a Key Event in Cancer Development, *Molecular Cancer Research*, Vol. 4, No. 4, 221–233. doi:10.1158/1541-7786.MCR-05-0261.
35. Lin, R., Zhang, C., Zheng, J., Tian, D., Lei, Z., Chen, D., Xu, Z., and Su, M. (2016). Chronic Inflammation-Associated Genomic Instability Paves the Way for Human Esophageal Carcinogenesis, *Oncotarget*, Vol. 7, No. 17, 24564–24571. doi:10.18632/oncotarget.8356.
36. Rajarubendra, N., Lawrentschuk, N., Bolton, D. M., Klotz, L., and Davis, I. D. (2011). Prostate Cancer Immunology – an Update for Urologists, *BJU International*, Vol. 107, No. 7, 1046–1051. doi:10.1111/j.1464-410X.2010.09820.x.
37. Elkord, E. (2007). Immunology and Immunotherapy Approaches for Prostate Cancer, *Prostate Cancer and Prostatic Diseases*, Vol. 10, No. 3, 224–236. doi:10.1038/sj.pcan.4500964.

38. Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., and Wei, X. (2022). Cancer Vaccines as Promising Immuno-Therapeutics: Platforms and Current Progress, *Journal of Hematology & Oncology*, Vol. 15, No. 1, 28. doi:10.1186/s13045-022-01247-x.

39. Li, M. (2024). The Mechanism of Action of Cancer Therapeutic Vaccines and Their Application Prospects, *Transactions on Materials, Biotechnology and Life Sciences*, Vol. 3, 694–700. doi:10.62051/2w95tb51.

40. Melssen, M., and Slingluff, C. L. (2017). Vaccines Targeting Helper T Cells for Cancer Immunotherapy, *Current Opinion in Immunology*, Vol. 47, 85–92. doi:10.1016/j.coi.2017.07.004.

41. Ostrand-Rosenberg, S. (2005). $CD4^+$ T Lymphocytes: A Critical Component of Antitumor Immunity, *Cancer Investigation*, Vol. 23, No. 5, 413–419. doi:10.1081/CNV-67428.

42. Raskov, H., Orhan, A., Christensen, J. P., and Gögenur, I. (2021). Cytotoxic CD8+ T Cells in Cancer and Cancer Immunotherapy, *British Journal of Cancer*, Vol. 124, No. 2, 359–367. doi:10.1038/s41416-020-01048-4.

43. Vacca, P., Munari, E., Tumino, N., Moretta, F., Pietra, G., Vitale, M., Del Zotto, G., Mariotti, F. R., Mingari, M. C., and Moretta, L. (2018). Human Natural Killer Cells and Other Innate Lymphoid Cells in Cancer: Friends or Foes?, *Immunology Letters*, Vol. 201, 14–19. doi:10.1016/j.imlet.2018.11.004.

44. Zöphel, D., Angenendt, A., Kaschek, L., Ravichandran, K., Hof, C., Janku, S., Hoth, M., and Lis, A. (2022). Faster Cytotoxicity with Age: Increased Perforin and Granzyme Levels in Cytotoxic CD8 + T Cells Boost Cancer Cell Elimination, *Aging Cell*, Vol. 21, No. 8, e13668. doi:10.1111/acel.13668.

45. Palmer, D. C., Balasubramaniam, S., Hanada, K., Wrzesinski, C., Yu, Z., Farid, S., Theoret, M. R., Hwang, L. N., Klebanoff, C. A., Gattinoni, L., Goldstein, A. L., Yang, J. C., and Restifo, N. P. (2004). Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously While Mediating Specific Tumor Destruction1, *The Journal of Immunology*, Vol. 173, No. 12, 7209–7216. doi:10.4049/jimmunol.173.12.7209.

46. Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., Heimann, D. M., Klebanoff, C. A., Yu, Z., Hwang, L. N., Feigenbaum, L., Kruisbeek, A. M., Rosenberg, S. A., and Restifo, N. P. (2003). Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-Reactive CD8+ T Cells, *Journal of Experimental Medicine*, Vol. 198, No. 4, 569–580. doi:10.1084/jem.20030590.

47. Oh, D. Y., and Fong, L. (2021). Cytotoxic CD4+ T Cells in Cancer: Expanding the Immune Effector Toolbox, *Immunity*, Vol. 54, No. 12, 2701–2711. doi:10.1016/j.immuni.2021.11.015.

48. Melssen, M., and Slingluff, C. L. (2017). Vaccines Targeting Helper T Cells for Cancer Immunotherapy, *Current Opinion in Immunology*, Vol. 47, 85–92. doi:10.1016/j.coi.2017.07.004.

49. Tay, R. E., Richardson, E. K., and Toh, H. C. (2021). Revisiting the Role of CD4+ T Cells in Cancer Immunotherapy—New Insights into Old Paradigms, *Cancer Gene Therapy*, Vol. 28, No. 1, 5–17. doi:10.1038/s41417-020-0183-x.

50. Kravtsov, D. S., Erbe, A. K., Sondel, P. M., and Rakhmilevich, A. L. (2022). Roles of CD4+ T Cells as Mediators of Antitumor Immunity, *Frontiers in Immunology*, Vol. 13. doi:10.3389/fimmu.2022.972021.

51. Schirrmacher, V. (2020). New Insights into Mechanisms of Long-Term Protective Anti-Tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection, *Biomedicines*, Vol. 8, No. 3, 55. doi:10.3390/biomedicines8030055.

52. Heath, E. I., Thakur, A., Chen, W., Hwang, C., Paller, C. J., Cackowski, F. C., Boerner, J. L., Heilbrun, L., Smith, M. P., Schalk, D. L., Schienschang, A., Whitaker, S. A., Polend, A., Smith, D., Vaishampayan, U. N., Dickow, B., and Lum, L. G. (2024). Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer, *Cancer Research Communications*, Vol. 4, No. 7, 1715–1725. doi:10.1158/2767-9764.CRC-24-0112.

53. Kissick, H. T., Sanda, M. G., Dunn, L. K., and Arredouani, M. S. (2014). Immunization with a Peptide Containing MHC Class I and II Epitopes Derived from the Tumor Antigen SIM2 Induces an Effective CD4 and CD8 T-Cell Response, *PLoS ONE*, Vol. 9, No. 4, e93231. doi:10.1371/journal.pone.0093231.

54. Zhang, B., Liu, J., Mo, Y., Zhang, K., Huang, B., and Shang, D. (2024). CD8+ T Cell Exhaustion and Its Regulatory Mechanisms in the Tumor Microenvironment: Key to the Success of Immunotherapy, *Frontiers in Immunology*, Vol. 15, 1476904. doi:10.3389/fimmu.2024.1476904.

55. Jiang, Y., Li, Y., and Zhu, B. (2015). T-Cell Exhaustion in the Tumor Microenvironment, *Cell Death & Disease*, Vol. 6, No. 6, e1792–e1792. doi:10.1038/cddis.2015.162.

56. Stone, L. (2023). Singling out the Immune-Suppressive TME in Prostate Cancer, *Nature Reviews Urology*, Vol. 20, No. 4, 199–199. doi:10.1038/s41585-023-00758-7.

57. Wang, C., Singer, M., and Anderson, A. C. (2017). Molecular Dissection of CD8+ T Cell Dysfunction, *Trends in Immunology*, Vol. 38, No. 8, 567–576. doi:10.1016/j.it.2017.05.008.

58. Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., and Zhang, Y. (2020). T Cell Dysfunction and Exhaustion in Cancer, *Frontiers in Cell and Developmental Biology*, Vol. 8, 17. doi:10.3389/fcell.2020.00017.

59. Minev, B., and Salgaller, M. L. (2004). Vaccines for the Immunotherapy of Prostate Cancer, M. A. Morse; T. M. Clay; H. K. Lyerly (Eds.), *Handbook of Cancer Vaccines*, Humana Press, Totowa, NJ, 451–464. doi:10.1007/978-1-59259-680-5_29.

60. Daniels, T., Zhang, J., Gutierrez, I., Elliot, M. L., Yamada, B., Heeb, M. J., Sheets, S. M., Wu, X., and Casiano, C. A. (2005). Antinuclear Autoantibodies in Prostate Cancer: Immunity to LEDGF/P75, a Survival Protein Highly Expressed in Prostate Tumors and Cleaved during Apoptosis, *The Prostate*, Vol. 62, No. 1, 14–26. doi:10.1002/pros.20112.

61. Cozzi, P., Kearsley, J., and Li, Y. (2008). Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy, *Current Cancer Therapy Reviews*, Vol. 4, No. 4, 271–284. doi:10.2174/157339408786413371.

62. Lopez Bujanda, Z. (Areli), Obradovic, A., Nirschl, T., O'Donnell, T., Laserson, U., Macedo-Gonzales, R., Reshef, R., Yuan, T., Soni, M., Antonarakis, E., Larman, B., Muranski, P., Drake, C., and Lopez Bujanda, Z. (Areli). (2020). 168 A Novel Prostate-Restricted Tumor-Associated Antigen: A Potential Therapeutic Target, *Regular and Young Investigator Award Abstracts*Presented at the 35th Anniversary Annual Meeting (SITC 2020), , BMJ Publishing Group Ltd, A101–A101. doi:10.1136/jitc-2020-SITC2020.0168.

63. Ghosh, A., Wang, X., Klein, E., and Heston, W. D. W. (2005). Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness, *Cancer Research*, Vol. 65, No. 3, 727–731. doi:10.1158/0008-5472.727.65.3.

64. Mhawech-Fauceglia, P., Zhang, S., Terracciano, L., Sauter, G., Chadhuri, A., Herrmann, F. R., and Penetrante, R. (2007). Prostate-Specific Membrane Antigen (PSMA) Protein Expression in Normal and Neoplastic Tissues and Its Sensitivity and Specificity in Prostate Adenocarcinoma: An Immunohistochemical Study Using Mutiple Tumour Tissue Microarray Technique, *Histopathology*, Vol. 50, No. 4, 472–483. doi:10.1111/j.1365-2559.2007.02635.x.

65. Giraudet, A.-L., Kryza, D., Hofman, M., Moreau, A., Fizazi, K., Flechon, A., Hicks, R. J., and Tran, B. (2021). PSMA Targeting in Metastatic Castration-Resistant Prostate Cancer: Where Are We and Where Are We Going?, *Therapeutic Advances in Medical Oncology*, Vol. 13, 17588359211053898. doi:10.1177/17588359211053898.

66. Tagawa, S. T., Beltran, H., Vallabhajosula, S., Goldsmith, S. J., Osborne, J., Matulich, D., Petrillo, K., Parmar, S., Nanus, D. M., and Bander, N. H. (2010). Anti-Prostate Specific Membrane Antigen-Based Radioimmunotherapy for Prostate Cancer, *Cancer*, Vol. 116, No. 4 Suppl, 1075–1083. doi:10.1002/cncr.24795.

67. Vu, P. L., Vadakekolathu, J., Idri, S., Nicholls, H., Cavaignac, M., Reeder, S., Khan, M. A., Christensen, D., Pockley, A. G., and

McArdle, S. E. (2022). A Mutated Prostatic Acid Phosphatase (PAP) Peptide-Based Vaccine Induces PAP-Specific CD8+ T Cells with Ex Vivo Cytotoxic Capacities in HHDII/DR1 Transgenic Mice, *Cancers*, Vol. 14, No. 8, 1970. doi:10.3390/cancers14081970.

68. Ercole, C. J., Lange, P. H., Mathisen, M., Chiou, R. K., Reddy, P. K., and Vessella, R. L. (1987). Prostatic Specific Antigen and Prostatic Acid Phosphatase in the Monitoring and Staging of Patients with Prostatic Cancer, *The Journal of Urology*, Vol. 138, No. 5, 1181–1184. doi:10.1016/s0022-5347(17)43543-9.

69. Höti, N., Lih, T.-S., Dong, M., Zhang, Z., Mangold, L., Partin, A. W., Sokoll, L. J., Kay Li, Q., and Zhang, H. (2023). Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection, *Cancers*, Vol. 15, No. 3, 960. doi:10.3390/cancers15030960.

70. Merriel, S. W. D., Pocock, L., Gilbert, E., Creavin, S., Walter, F. M., Spencer, A., and Hamilton, W. (2022). Systematic Review and Meta-Analysis of the Diagnostic Accuracy of Prostate-Specific Antigen (PSA) for the Detection of Prostate Cancer in Symptomatic Patients, *BMC Medicine*, Vol. 20, 54. doi:10.1186/s12916-021-02230-y.

71. Merkens, L., Sailer, V., Lessel, D., Janzen, E., Greimeier, S., Kirfel, J., Perner, S., Pantel, K., Werner, S., and von Amsberg, G. (2022). Aggressive Variants of Prostate Cancer: Underlying Mechanisms of Neuroendocrine Transdifferentiation, *Journal of Experimental & Clinical Cancer Research*, Vol. 41, No. 1, 46. doi:10.1186/s13046-022-02255-y.

72. Yamasaki, S., Shimizu, K., and Fujii, S.-I. (2024). Tumor Epitope Spreading by a Novel Multivalent Therapeutic Cellular Vaccine Targeting Cancer Antigens to Invariant NKT-Triggered Dendritic Cells in Situ, *Frontiers in Immunology*, Vol. 15, 1345037. doi:10.3389/fimmu.2024.1345037.

73. St. John, J., Powell, K., Conley-LaComb, M. K., and Chinni, S. R. (2012). TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression, *Journal of Cancer Science & Therapy*, Vol. 4, No. 4, 94–101. doi:10.4172/1948-5956.1000119.

74. Bilusic, M., McMahon, S., Madan, R. A., Karzai, F., Tsai, Y.-T., Donahue, R. N., Palena, C., Jochems, C., Marté, J. L., Floudas, C., Strauss, J., Redman, J., Sater, H. A., Rabizadeh, S., Soon-Shiong, P., Schlom, J., and Gulley, J. L. (2021). Phase I Study of a Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy Vaccine in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC), *Journal for ImmunoTherapy of Cancer*, Vol. 9, No. 3, e002374. doi:10.1136/jitc-2021-002374.

75. Gao, T., Cen, Q., and Lei, H. (2020). A Review on Development of MUC1-Based Cancer Vaccine, *Biomedicine & Pharmacotherapy*, Vol. 132, 110888. doi:10.1016/j.biopha.2020.110888.

76. North, S. A., Graham, K., Bodnar, D., and Venner, P. (2006). A Pilot Study of the Liposomal MUC1 Vaccine BLP25 in Prostate Specific Antigen Failures After Radical Prostatectomy, *The Journal of Urology*, Vol. 176, No. 1, 91–95. doi:10.1016/S0022-5347(06)00494-0.

77. Cai, Y., Chen, R., Gao, S., Li, W., Liu, Y., Su, G., Song, M., Jiang, M., Jiang, C., and Zhang, X. (2023). Artificial Intelligence Applied in Neoantigen Identification Facilitates Personalized Cancer Immunotherapy, *Frontiers in Oncology*, Vol. 12, 1054231. doi:10.3389/fonc.2022.1054231.

78. Olawade, D. B., Teke, J., Fapohunda, O., Weerasinghe, K., Usman, S. O., Ige, A. O., and Clement David-Olawade, A. (2024). Leveraging Artificial Intelligence in Vaccine Development: A Narrative Review, *Journal of Microbiological Methods*, Vol. 224, 106998. doi:10.1016/j.mimet.2024.106998.

79. Hu, Z., Leet, D. E., Allesøe, R. L., Oliveira, G., Li, S., Luoma, A. M., Liu, J., Forman, J., Huang, T., Iorgulescu, J. B., Holden, R., Sarkizova, S., Gohil, S. H., Redd, R. A., Sun, J., Elagina, L., Giobbie-Hurder, A., Zhang, W., Peter, L., Ciantra, Z., Rodig, S., Olive, O., Shetty, K., Pyrdol, J., Uduman, M., Lee, P. C., Bachireddy, P., Buchbinder, E. I., Yoon, C. H., Neuberg, D., Pentelute, B. L., Hacohen, N., Livak, K. J., Shukla, S. A., Olsen, L. R., Barouch, D. H., Wucherpfennig, K. W., Fritsch, E. F., Keskin, D. B., Wu, C. J., and Ott, P. A. (2021). Personal Neoantigen Vaccines Induce Persistent Memory T Cell Responses and Epitope Spreading in Patients with Melanoma, *Nature Medicine*, Vol. 27, No. 3, 515–525. doi:10.1038/s41591-020-01206-4.

80. Kellermann, G., Leulliot, N., Cherfils-Vicini, J., Blaud, M., and Brest, P. (2024). Activated B-Cells Enhance Epitope Spreading to Support Successful Cancer Immunotherapy, *Frontiers in Immunology*, Vol. 15, 1382236. doi:10.3389/fimmu.2024.1382236.

81. Jähnisch, H., Füssel, S., Kiessling, A., Wehner, R., Zastrow, S., Bachmann, M., Rieber, E. P., Wirth, M. P., and Schmitz, M. (2010). Dendritic Cell-Based Immunotherapy for Prostate Cancer, *Journal of Immunology Research*, Vol. 2010, No. 1, 517493. doi:10.1155/2010/517493.

82. Sutherland, S. I. M., Ju, X., Horvath, L. G., and Clark, G. J. (2021). Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer, *Frontiers in Immunology*, Vol. 12, 641307. doi:10.3389/fimmu.2021.641307.

83. Bakhshi, P., Nourizadeh, M., Sharifi, L., Nowroozi, M. R., Mohsenzadegan, M., and Farajollahi, M. M. (2024). Impaired Monocyte-derived Dendritic Cell Phenotype in Prostate Cancer Patients: A Phenotypic Comparison with Healthy Donors, *Cancer Reports*, Vol. 7, No. 2, e1996. doi:10.1002/cnr2.1996.

84. Caram, M. E. V., Ross, R., Lin, P., and Mukherjee, B. (2019). Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer, *JAMA Network Open*, Vol. 2, No. 4, e192589. doi:10.1001/jamanetworkopen.2019.2589.

85. Anjum, S., Naseer, F., Ahmad, T., Liaquat, A., Abduh, M. S., and Kousar, K. (2024). Co-delivery of Oncolytic Virus and Chemotherapeutic Modality: Vincristine against Prostate Cancer Treatment: A Potent Viro-chemotherapeutic Approach, *Journal of Medical Virology*, Vol. 96, No. 7, e29748. doi:10.1002/jmv.29748.

86. Graham, J. B. (2010, May). *Co-delivery of cationic polymers and adenovirus in immunotherapy of prostate cancer* (Doctor of Philosophy)University of Iowa, Iowa City, IA, United StatesRetrieved from https://iro.uiowa.edu/esploro/outputs/doctoral/9983777066502771.

87. Sardinha, M., Palma Dos Reis, A. F., Barreira, J. V., Fontes Sousa, M., Pacey, S., and Luz, R. (2023). Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review, *Cureus*. doi:10.7759/cureus.34490.

88. D'Apice, L., Costa, V., Sartorius, R., Trovato, M., Aprile, M., and De Berardinis, P. (2015). Stimulation of Innate and Adaptive Immunity by Using Filamentous Bacteriophage Fd Targeted to DEC-205, *Journal of Immunology Research*, Vol. 2015, 1–11. doi:10.1155/2015/585078.

89. Kim, J. J., Yang, J. S., Dang, K., Manson, K. H., and Weiner, D. B. (2001). Engineering Enhancement of Immune Responses to DNA-Based Vaccines in a Prostate Cancer Model in Rhesus Macaques through the Use of Cytokine Gene Adjuvants, *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, Vol. 7, No. 3 Suppl, 882s–889s.

90. Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., Vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., Jocham, D., Maurer, T., Rippin, G., Fotin-Mleczek, M., Von Der Mülbe, F., Probst, J., Hoerr, I., Kallen, K.-J., Lander, T., and Stenzl, A. (2015). Self-Adjuvanted mRNA Vaccination in Advanced Prostate Cancer Patients: A First-in-Man Phase I/IIa Study, *Journal for Immunotherapy of Cancer*, Vol. 3, No. 1, 26. doi:10.1186/s40425-015-0068-y.

91. Hou, X., Zaks, T., Langer, R., and Dong, Y. (2021). Lipid Nanoparticles for mRNA Delivery, *Nature Reviews Materials*, Vol. 6, No. 12, 1078–1094. doi:10.1038/s41578-021-00358-0.

92. Lu, B., Lim, J. M., Yu, B., Song, S., Neeli, P., Sobhani, N., K, P., Bonam, S. R., Kurapati, R., Zheng, J., and Chai, D. (2024). The Next-Generation DNA Vaccine Platforms and Delivery Systems: Advances, Challenges and Prospects, *Frontiers in Immunology*, Vol. 15, 1332939. doi:10.3389/fimmu.2024.1332939.

93. Rakoczy, K., Kisielewska, M., Sędzik, M., Jonderko, L., Celińska, J., Sauer, N., Szlasa, W., Saczko, J., Novickij, V., and Kulbacka, J. (2022). Electroporation in Clinical Applications—The Potential of Gene Electrotransfer and Electrochemotherapy, *Applied Sciences*, Vol. 12, No. 21, 10821. doi:10.3390/app122110821.

94. Larsen, S. E., Erasmus, J. H., Reese, V. A., Pecor, T., Archer, J., Kandahar, A., Hsu, F.-C., Nicholes, K., Reed, S. G., Baldwin, S. L., and Coler, R. N. (2023). An RNA-Based Vaccine Platform for Use against Mycobacterium Tuberculosis, *Vaccines*, Vol. 11, No. 1, 130. doi:10.3390/vaccines11010130.

95. Leitner, W. W., Ying, H., and Restifo, N. P. (1999). DNA and RNA-Based Vaccines: Principles, Progress and Prospects, *Vaccine*, Vol. 18, Nos. 9–10, 765–777.

96. Ahmad, S., Sweeney, P., Sullivan, G. C., and Tangney, M. (2012). DNA Vaccination for Prostate Cancer, from Preclinical to Clinical Trials - Where We Stand?, *Genetic Vaccines and Therapy*, Vol. 10, No. 1, 9. doi:10.1186/1479-0556-10-9.

97. Colluru, V. T., Johnson, L. E., Olson, B. M., and McNeel, D. G. (2016). Preclinical and Clinical Development of DNA Vaccines for Prostate Cancer, *Urologic Oncology: Seminars and Original Investigations*, Vol. 34, No. 4, 193–204. doi:10.1016/j.urolonc.2013.09.014.

98. Rausch, S., Schwentner, C., Stenzl, A., and Bedke, J. (2014). mRNA Vaccine CV9103 and CV9104 for the Treatment of Prostate Cancer, *Human Vaccines & Immunotherapeutics*, Vol. 10, No. 11, 3146–3152. doi:10.4161/hv.29553.

99. Arlen, P. M., Gulley, J. L., Tsang, K.-Y., and Schlom, J. (2003). Strategies for the Development of PSA-Based Vaccines for the Treatment of Advanced Prostate Cancer, *Expert Review of Vaccines*, Vol. 2, No. 4, 483–493. doi:10.1586/14760584.2.4.483.

100. Li, J., Sun, Y., Jia, T., Zhang, R., Zhang, K., and Wang, L. (2014). Messenger RNA Vaccine Based on Recombinant MS2 Virus-like Particles against Prostate Cancer, *International Journal of Cancer*, Vol. 134, No. 7, 1683–1694. doi:10.1002/ijc.28482.

101. Gao, Y., Yang, L., Li, Z., Peng, X., and Li, H. (2024). mRNA Vaccines in Tumor Targeted Therapy: Mechanism, Clinical Application, and Development Trends, *Biomarker Research*, Vol. 12, No. 1, 93. doi:10.1186/s40364-024-00644-3.

102. Madan, R. A., Gulley, J. L., and Arlen, P. M. (2006). PSA-Based Vaccines for the Treatment of Prostate Cancer, *Expert Review of Vaccines*, Vol. 5, No. 2, 199–209. doi:10.1586/14760584.5.2.199.

103. Skwarczynski, M., and Toth, I. (2016). Peptide-Based Synthetic Vaccines, *Chemical Science*, Vol. 7, No. 2, 842–854. doi:10.1039/c5sc03892h.

104. Paston, S. J., Brentville, V. A., Symonds, P., and Durrant, L. G. (2021). Cancer Vaccines, Adjuvants, and Delivery Systems, *Frontiers in Immunology*, Vol. 12. doi:10.3389/fimmu.2021.627932.

105. Abd-Aziz, N., and Poh, C. L. (2022). Development of Peptide-Based Vaccines for Cancer, *Journal of Oncology*, Vol. 2022, 9749363. doi:10.1155/2022/9749363.

106. Potluri, H. K., Ng, T. L., Newton, M. A., and McNeel, D. G. (2022). GM-CSF Elicits Antibodies to Tumor-Associated Proteins When Used as a Prostate Cancer Vaccine Adjuvant, *Cancer Immunology, Immunotherapy: CII*, Vol. 71, No. 9, 2267–2275. doi:10.1007/s00262-022-03150-3.

107. Disis, M. L., Bernhard, H., Shiota, F. M., Hand, S. L., Gralow, J. R., Huseby, E. S., Gillis, S., and Cheever, M. A. (1996). Granulocyte-Macrophage Colony-Stimulating Factor: An Effective Adjuvant for Protein and Peptide-Based Vaccines, *Blood*, Vol. 88, No. 1, 202–210.

108. Obara, W., Sato, F., Takeda, K., Kato, R., Kato, Y., Kanehira, M., Takata, R., Mimata, H., Sugai, T., Nakamura, Y., and Fujioka, T. (2017). Phase I Clinical Trial of Cell Division Associated 1 (CDCA 1) Peptide Vaccination for Castration Resistant Prostate Cancer, *Cancer Science*, Vol. 108, No. 7, 1452–1457. doi:10.1111/cas.13278.

109. Hueman, M. T., Dehqanzada, Z. A., Novak, T. E., Gurney, J. M., Woll, M. M., Ryan, G. B., Storrer, C. E., Fisher, C., McLeod, D. G., Ioannides, C. G., Ponniah, S., and Peoples, G. E. (2005). Phase I Clinical Trial of a HER-2/ *Neu* Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients, *Clinical Cancer Research*, Vol. 11, No. 20, 7470–7479. doi:10.1158/1078-0432.CCR-05-0235.

110. Meye, A., Fuessel, S., Schmitz, M., Zastrow, S., Linne, C., Richter, K., Lobel, B., Hakenberg, O. W., Hoelig, K., Rieber, P. E., and Wirth, M. P. (2006). Vaccination of Hormone-Refractory Prostate Cancer Patients with Peptide Cocktail-Loaded Dendritic Cells: Results of a Phase I Clinical Trial, *Journal of Clinical Oncology*, Vol. 24, No. 18_suppl, 2551–2551. doi:10.1200/jco.2006.24.18_suppl.2551.

111. Taylor, B. C., and Balko, J. M. (2022). Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response, *Frontiers in Immunology*, Vol. 13. doi:10.3389/fimmu.2022.844866.

112. Carretero, F. J., del Campo, A. B., Flores-Martín, J. F., Mendez, R., García-Lopez, C., Cozar, J. M., Adams, V., Ward, S., Cabrera, T., Ruiz-Cabello, F., Garrido, F., and Aptsiauri, N. (2015). Frequent HLA Class I Alterations in Human Prostate Cancer: Molecular Mechanisms and Clinical Relevance, *Cancer Immunology, Immunotherapy : CII*, Vol. 65, No. 1, 47–59. doi:10.1007/s00262-015-1774-5.

113. Obara, W., Kanehira, M., Katagiri, T., Kato, R., Kato, Y., and Takata, R. (2018). Present Status and Future Perspective of Peptide-based Vaccine Therapy for Urological Cancer, *Cancer Science*, Vol. 109, No. 3, 550–559. doi:10.1111/cas.13506.

114. Mohite, P., Yadav, V., Pandhare, R., Maitra, S., Saleh, F. M., Saleem, R. M., Al-malky, H. S., Kumarasamy, V., Subramaniyan, V., Abdel-Daim, M. M., and Uti, D. E. (2024). Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy, *ACS Omega*, Vol. 9, No. 7, 7277–7295. doi:10.1021/acsomega.3c06501.

115. Ragothaman, M., and Yoo, S. Y. (2023). Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions, *Vaccines*, Vol. 11, No. 5, 919. doi:10.3390/vaccines11050919.

116. Madan, R. A., Arlen, P. M., Mohebtash, M., Hodge, J. W., and Gulley, J. L. (2009). Prostvac-VF: A Vector-Based Vaccine Targeting PSA in Prostate Cancer, *Expert Opinion on Investigational Drugs*, Vol. 18, No. 7, 1001–1011. doi:10.1517/13543780902997928.

117. Madan, R. A., Heery, C. R., and Gulley, J. L. (2014). Poxviral-Based Vaccine Elicits Immunologic Responses in Prostate Cancer Patients, *OncoImmunology*, Vol. 3, No. 5, e28611. doi:10.4161/onci.28611.

118. Klyushnenkova, E. N., Kouiavskaia, D. V., Parkins, C. J., Caposio, P., Botto, S., Alexander, R. B., and Jarvis, M. A. (2012). A Cytomegalovirus-Based Vaccine Expressing a Single Tumor-Specific CD8+ T-Cell Epitope Delays Tumor Growth in a Murine Model of Prostate Cancer, *Journal of Immunotherapy*, Vol. 35, No. 5, 390–399. doi:10.1097/CJI.0b013e3182585d50.

119. Sasso, E., D'Alise, A. M., Zambrano, N., Scarselli, E., Folgori, A., and Nicosia, A. (2020). New Viral Vectors for Infectious Diseases and Cancer, *Seminars in Immunology*, Vol. 50, 101430. doi:10.1016/j.smim.2020.101430.

120. Lubaroff, D. M., Konety, B. R., Link, B., Gerstbrein, J., Madsen, T., Shannon, M., Howard, J., Paisley, J., Boeglin, D., Ratliff, T. L., and Williams, R. D. (2009). Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results, *Clinical Cancer Research*, Vol. 15, No. 23, 7375–7380. doi:10.1158/1078-0432.CCR-09-1910.

121. Kaufman, H. L., Wang, W., Manola, J., DiPaola, R. S., Ko, Y.-J., Sweeney, C., Whiteside, T. L., Schlom, J., Wilding, G., and Weiner, L. M. (2004). Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group, *Journal of Clinical Oncology*, Vol. 22, No. 11, 2122–2132. doi:10.1200/JCO.2004.08.083.

122. Fukuhara, H., Homma, Y., and Todo, T. (2010). Oncolytic Virus Therapy for Prostate Cancer, *International Journal of Urology*, Vol. 17, No. 1, 20–30. doi:10.1111/j.1442-2042.2009.02383.x.

123. Larocca, C., and Schlom, J. (2011). Viral Vector –Based Therapeutic Cancer Vaccines, *Cancer Journal (Sudbury, Mass.)*, Vol. 17, No. 5, 359–371. doi:10.1097/PPO.0b013e3182325e63.

124. Saxena, M., Van, T. T. H., Baird, F. J., Coloe, P. J., and Smooker, P. M. (2013). Pre-Existing Immunity against Vaccine Vectors – Friend or Foe?, *Microbiology*, Vol. 159, No. Pt 1, 1–11. doi:10.1099/mic.0.049601-0.

125. Cappuccini, F., Bryant, R., Pollock, E., Carter, L., Verrill, C., Hollidge, J., Poulton, I., Baker, M., Mitton, C., Baines, A., Meier, A., Schmidt, G., Harrop, R., Protheroe, A., MacPherson, R., Kennish, S., Morgan, S., Vigano, S., Romero, P. J., Evans, T., Catto, J., Hamdy, F., Hill, A. V. S., and Redchenko, I. (2020). Safety and Immunogenicity of Novel 5T4 Viral Vectored Vaccination Regimens in Early Stage Prostate Cancer: A Phase I Clinical Trial, *Journal for ImmunoTherapy of Cancer*, Vol. 8, No. 1, e000928. doi:10.1136/jitc-2020-000928.

126. Schuhmacher, J., Heidu, S., Balchen, T., Richardson, J. R., Schmeltz, C., Sonne, J., Schweiker, J., Rammensee, H.-G., Thor Straten, P., Røder, M. A., Brasso, K., and Gouttefangeas, C. (2020). Vaccination against RhoC Induces Long-Lasting Immune Responses in Patients with Prostate Cancer: Results from a Phase I/II Clinical Trial, *Journal for ImmunoTherapy of Cancer*, Vol. 8, No. 2, e001157. doi:10.1136/jitc-2020-001157.

127. Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., Pook, D. W., Rathenborg, P., Flaig, T. W., Carles, J., Saad, F., Shore, N. D., Chen, L., Heery, C. R., Gerritsen, W. R., Priou, F., Langkilde, N. C., Novikov, A., and Kantoff, P. W. (2019). Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer, *Journal of Clinical Oncology*, Vol. 37, No. 13, 1051–1061. doi:10.1200/JCO.18.02031.

128. Vilaça, M., Correia Pinto, J., Magalhães, H., Reis, F., and Mesquita, A. (n.d.). Tumor-Infiltrating Lymphocytes in Localized Prostate Cancer: Do They Play an Important Role?, *Cureus*, Vol. 15, No. 1, e34007. doi:10.7759/cureus.34007.

129. Mao, C., Ding, Y., and Xu, N. (2021). A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy, *Frontiers in Oncology*, Vol. 11, 688489. doi:10.3389/fonc.2021.688489.

130. Jiang, W., He, Y., He, W., Wu, G., Zhou, X., Sheng, Q., Zhong, W., Lu, Y., Ding, Y., Lu, Q., Ye, F., and Hua, H. (2021). Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy, *Frontiers in Immunology*, Vol. 11, 622509. doi:10.3389/fimmu.2020.622509.

131. Mantovani, A., Romero, P., Palucka, A. K., and Marincola, F. M. (2008). Tumour Immunity: Effector Response to Tumour and Role of the Microenvironment, *Lancet (London, England)*, Vol. 371, No. 9614, 771–783. doi:10.1016/S0140-6736(08)60241-X.

132. Thomas, R., Jerome, J. M., Krieger, K. L., Ashraf, N., and Rowley, D. R. (2024). The Reactive Stroma Response Regulates the Immune Landscape in Prostate Cancer, *Journal of Translational Genetics and Genomics*, Vol. 8, No. 3, 249–277. doi:10.20517/jtgg.2024.15.

133. Tie, Y., Tang, F., Wei, Y., and Wei, X. (2022). Immunosuppressive Cells in Cancer: Mechanisms and Potential Therapeutic Targets, *Journal of Hematology & Oncology*, Vol. 15, No. 1, 61. doi:10.1186/s13045-022-01282-8.

134. Kim, S. K., and Cho, S. W. (2022). The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment, *Frontiers in Pharmacology*, Vol. 13, 868695. doi:10.3389/fphar.2022.868695.

135. Zahm, C. D., Moseman, J. E., Delmastro, L. E., and G. Mcneel, D. (n.d.). PD-1 and LAG-3 Blockade Improve Anti-Tumor Vaccine Efficacy, *Oncoimmunology*, Vol. 10, No. 1, 1912892. doi:10.1080/2162402X.2021.1912892.

136. Japp, A. S., Kursunel, M. A., Meier, S., Mälzer, J. N., Li, X., Rahman, N. A., Jekabsons, W., Krause, H., Magheli, A., Klopf, C., Thiel, A., and Frentsch, M. (2015). Dysfunction of PSA-Specific CD8+ T Cells in Prostate Cancer Patients Correlates with CD38 and Tim-3 Expression, *Cancer Immunology, Immunotherapy : CII*, Vol. 64, No. 11, 1487–1494. doi:10.1007/s00262-015-1752-y.

137. Bettonville, M., d'Aria, S., Weatherly, K., Porporato, P. E., Zhang, J., Bousbata, S., Sonveaux, P., and Braun, M. Y. (n.d.). Long-Term Antigen Exposure Irreversibly Modifies Metabolic Requirements for T Cell Function, *eLife*, Vol. 7, e30938. doi:10.7554/eLife.30938.

138. Mulvey, A., Muggeo-Bertin, E., Berthold, D. R., and Herrera, F. G. (2022). Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer, *Frontiers in Immunology*, Vol. 13, 859785. doi:10.3389/fimmu.2022.859785.

139. Gujar, S. A., Pan, D., Marcato, P., Garant, K. A., and Lee, P. W. (2011). Oncolytic Virus-Initiated Protective Immunity Against Prostate Cancer, *Molecular Therapy*, Vol. 19, No. 4, 797–804. doi:10.1038/mt.2010.297.

140. Fu, R., Qi, R., Xiong, H., Lei, X., Jiang, Y., He, J., Chen, F., Zhang, L., Qiu, D., Chen, Y., Nie, M., Guo, X., Zhu, Y., Zhang, J., Yue, M., Cao, J., Wang, G., Que, Y., Fang, M., Wang, Y., Chen, Y., Cheng, T., Ge, S., Zhang, J., Yuan, Q., Zhang, T., and Xia, N. (2024). Combination Therapy with Oncolytic Virus and T Cells or mRNA Vaccine Amplifies Antitumor Effects, *Signal Transduction and Targeted Therapy*, Vol. 9, No. 1, 1–14. doi:10.1038/s41392-024-01824-1.

141. Tan, S., Wang, K., Sun, F., Li, Y., and Gao, Y. (2018). CXCL9 Promotes Prostate Cancer Progression through Inhibition of Cytokines from T Cells, *Molecular Medicine Reports*, Vol. 18, No. 2, 1305–1310. doi:10.3892/mmr.2018.9152.

142. Bronger, H., Singer, J., Windmüller, C., Reuning, U., Zech, D., Delbridge, C., Dorn, J., Kiechle, M., Schmalfeldt, B., Schmitt, M., and Avril, S. (2016). CXCL9 and CXCL10 Predict Survival and Are Regulated by Cyclooxygenase Inhibition in Advanced Serous Ovarian Cancer, *British Journal of Cancer*, Vol. 115, No. 5, 553–563. doi:10.1038/bjc.2016.172.

143. Madan, R. A., Gulley, J. L., Schlom, J., Steinberg, S. M., Liewehr, D. J., Dahut, W. L., and Arlen, P. M. (2008). Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy, *Clinical Cancer Research*, Vol. 14, No. 14, 4526–4531. doi:10.1158/1078-0432.CCR-07-5048.

144. Bhasin, A., Mille, P. J., Eturi, A., Iskander, A., Tester, W., and Zarrabi, K. K. (2024). Tumor-Associated Antigen Targets for Novel Immune-Based Strategies in Prostate Cancer, *Journal of Translational Genetics and Genomics*, Vol. 8, No. 1, 55–76. doi:10.20517/jtgg.2023.46.

145. Kiessling, A., Wehner, R., Füssel, S., Bachmann, M., Wirth, M. P., and Schmitz, M. (2012). Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer, *Cancers*, Vol. 4, No. 1, 193–217. doi:10.3390/cancers4010193.

146. Liu, J., Li, Y., Yang, D., Yang, C., and Mao, L. (2019). Current State of Biomarkers for the Diagnosis and Assessment of Treatment Efficacy of Prostate Cancer, *Discovery Medicine*, Vol. 27, No. 150, 235–243.

147. Sheikh, N. A., Petrylak, D., Kantoff, P. W., dela Rosa, C., Stewart, F. P., Kuan, L.-Y., Whitmore, J. B., Trager, J. B., Poehlein, C. H., Frohlich, M. W., and Urdal, D. L. (2012). Sipuleucel-T Immune Parameters Correlate with Survival: An Analysis of the Randomized Phase 3 Clinical Trials in Men with Castration-Resistant Prostate Cancer, *Cancer Immunology, Immunotherapy : CII*, Vol. 62, No. 1, 137–147. doi:10.1007/s00262-012-1317-2.

148. Cha, E., and Fong, L. (2011). Immunotherapy for Prostate Cancer: Biology and Therapeutic Approaches, *Journal of Clinical Oncology*, Vol. 29, No. 27, 3677–3685. doi:10.1200/JCO.2010.34.5025.

149. Le, D. T., and Jaffee, E. M. (2013). Next-Generation Cancer Vaccine Approaches: Integrating Lessons Learned From Current Successes With Promising Biotechnologic Advances, *Journal of the National Comprehensive Cancer Network : JNCCN*, Vol. 11, No. 7, 766–772.

150. Wang, J., Zhou, K., Zhu, H., Wei, F., Ma, S., Kan, Y., Li, B., and Mao, L. (2023). Current Status and Progress of the Development of Prostate Cancer Vaccines, *Journal of Cancer*, Vol. 14, No. 5, 835–842. doi:10.7150/jca.80803.

151. Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., and Blankschtein, D. (2016). mRNA Vaccine Delivery Using Lipid

Nanoparticles, *Therapeutic Delivery*, Vol. 7, No. 5, 319–334. doi:10.4155/tde-2016-0006.

152. Small, E. J., and Fong, L. (2010). Developing Immunotherapy As Legitimate Therapy for Patients With Prostate Cancer, *Journal of Clinical Oncology*, Vol. 28, No. 7, 1085–1087. doi:10.1200/JCO.2009.26.3483.

153. Yun, J. W., Lee, S., Ryu, D., Park, S., Park, W.-Y., Joung, J.-G., and Jeong, J. (2018). Biomarkers Associated with Tumor Heterogeneity in Prostate Cancer, *Translational Oncology*, Vol. 12, No. 1, 43–48. doi:10.1016/j.tranon.2018.09.003.

154. Kim, J. W., and Gulley, J. L. (2012). Poxviral Vectors for Cancer Immunotherapy, *Expert Opinion on Biological Therapy*, Vol. 12, No. 4, 463–478. doi:10.1517/14712598.2012.668516.

155. Bou-Dargham, M. J., Sha, L., Sang, Q.-X. A., and Zhang, J. (2020). Immune Landscape of Human Prostate Cancer: Immune Evasion Mechanisms and Biomarkers for Personalized Immunotherapy, *BMC Cancer*, Vol. 20, No. 1, 572. doi:10.1186/s12885-020-07058-y.

156. Reva, B. A., Omelchenko, T., Nair, S. S., and Tewari, A. K. (2020). Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets, *Urologic Clinics of North America*, Vol. 47, Nos. 4, Supplement, e9–e16. doi:10.1016/j.ucl.2020.10.004.

157. Zhang, H., Patenaude, B., Ma, C., and Fang, H. (2023). Vaccine Pricing Strategies in China, *BMJ Global Health*, Vol. 8, No. 7, e011405. doi:10.1136/bmjgh-2022-011405.

158. Jaroslawski, S., Caban, A., and Toumi, M. (2015). Sipuleucel-T (Provenge®): Autopsy of an Innovative Change of Paradigm in Cancer Treatment, *Value in Health*, Vol. 18, No. 7, A479. doi:10.1016/j.jval.2015.09.1294.

159. Baghdadi, R. (2010). Dendreon vs CMS: Why the Provenge Coverage Controversy Is Bigger than Just One Product, *Oncology (Williston Park, N.Y.)*, Vol. 24, No. 10, 881–883.

160. Madan, R. A., and Gulley, J. L. (2011). Sipuleucel-T: Harbinger of a New Age of Therapeutics for Prostate Cancer, *Expert Review of Vaccines*, Vol. 10, No. 2, 141–150. doi:10.1586/erv.10.173.

161. Andrews, A. (2015). Treating with Checkpoint Inhibitors—Figure $1 Million per Patient, *American Health & Drug Benefits*, Vol. 8, No. Spec Issue, 9.

162. Paul, J., Mitchell, A. P., Kesselheim, A. S., and Rome, B. N. (2024). Trends in Prices of Checkpoint Inhibitors in the US, 2016-2023., *Journal of Clinical Oncology*, Vol. 42, No. 16_suppl, 11075–11075. doi:10.1200/JCO.2024.42.16_suppl.11075.

163. PROSTVAC Misses Phase III Goal in Prostate Cancer. (2017, September 15). *OncLive*, from https://www.onclive.com/view/prostvac-misses-phase-iii-goal-in-prostate-cancer, accessed 9-2-2025.

164. Vatsan, R. S., Bross, P. F., Liu, K., Theoret, M., De Claro, A. R., Lu, J., Helms, W., Niland, B., Husain, S. R., and Puri, R. K. (2013). Regulation of Immunotherapeutic Products for Cancer and FDA's Role in Product Development and Clinical Evaluation, *Journal for Immunotherapy of Cancer*, Vol. 1, 5. doi:10.1186/2051-1426-1-5.

165. Gignac, G. A., Morris, M. J., Heller, G., Schwartz, L. H., and Scher, H. I. (2008). Assessing Outcomes in Prostate Cancer Clinical Trials: A Twenty-first Century Tower of Babel, *Cancer*, Vol. 113, No. 5, 966–974. doi:10.1002/cncr.23719.

166. Halabi, S., Vogelzang, N. J., Ou, S.-S., Owzar, K., Archer, L., and Small, E. J. (2009). Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer, *Journal of Clinical Oncology*, Vol. 27, No. 17, 2766–2771. doi:10.1200/JCO.2008.18.9159.

167. Yoshimura, K., Minami, T., Nozawa, M., Kimura, T., Egawa, S., Fujimoto, H., Yamada, A., Itoh, K., and Uemura, H. (2016). A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-Dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-Naive Castration-Resistant Prostate Cancer, *European Urology*, Vol. 70, No. 1, 35–41. doi:10.1016/j.eururo.2015.12.050.

168. Rehman, L. ur, Nisar, M. H., Fatima, W., Sarfraz, A., Azeem, N., Sarfraz, Z., Robles-Velasco, K., and Cherrez-Ojeda, I. (2023). Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives, *Journal of Clinical Medicine*, Vol. 12, No. 4, 1446. doi:10.3390/jcm12041446.

169. Halabi, S., Roy, A., Rydzewska, L., Guo, S., Godolphin, P., Hussain, M., Tangen, C., Thompson, I., Xie, W., Carducci, M. A., Smith, M. R., Morris, M. J., Gravis, G., Dearnaley, D. P., Verhagen, P., Goto, T., James, N., Buyse, M. E., Tierney, J. F., Sweeney, C., and Collaboration, on behalf of the S. (2024). Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer, *Journal of Clinical Oncology*. doi:10.1200/JCO.23.01535.

170. Redman, J. M., Gulley, J. L., and Madan, R. A. (2017). Combining Immunotherapies for the Treatment of Prostate Cancer, *Urologic Oncology: Seminars and Original Investigations*, Vol. 35, No. 12, 694–700. doi:10.1016/j.urolonc.2017.09.024.

171. Antonarakis, E. S. (2012). Combining Active Immunotherapy with Immune Checkpoint Blockade for the Treatment of Advanced Prostate Cancer, *Asian Journal of Andrology*, Vol. 14, No. 4, 520–521. doi:10.1038/aja.2012.45.

172. Singh, B. H., and Gulley, J. L. (2014). Therapeutic Vaccines as a Promising Treatment Modality against Prostate Cancer: Rationale and Recent Advances, *Therapeutic Advances in Vaccines*, Vol. 2, No. 5, 137–148. doi:10.1177/2051013614539478.

173. Collins, J. M., Redman, J. M., and Gulley, J. L. (2018). Combining Vaccines and Immune Checkpoint Inhibitors to Prime, Expand, and Facilitate Effective Tumor Immunotherapy, *Expert Review of Vaccines*, Vol. 17, No. 8, 697–705. doi:10.1080/14760584.2018.1506332.

174. Cecil, D. L., Curtis, B., Gad, E., Gormley, M., Timms, A. E., Corulli, L., Bos, R., Damle, R. N., Sepulveda, M. A., and Disis, M. L. (2022). Anti-Tumor Activity of a T-Helper 1 Multiantigen Vaccine in a Murine Model of Prostate Cancer, *Scientific Reports*, Vol. 12, No. 1, 13618. doi:10.1038/s41598-022-17950-1.

175. Zhang, L. (2018). Multi-Epitope Vaccines: A Promising Strategy against Tumors and Viral Infections, *Cellular and Molecular Immunology*, Vol. 15, No. 2, 182–184. doi:10.1038/cmi.2017.92.

176. Pfeifer, B. A., Beitelshees, M., Hill, A., Bassett, J., and Jones, C. H. (2023). Harnessing Synthetic Biology for Advancing RNA Therapeutics and Vaccine Design, *Npj Systems Biology and Applications*, Vol. 9, No. 1, 60. doi:10.1038/s41540-023-00323-3.

177. Ravindranathan, D., Russler, G. A., Yantorni, L., Drusbosky, L. M., and Bilen, M. A. (2021). Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series, *Case Reports in Oncology*, Vol. 14, No. 1, 190–196. doi:10.1159/000512819.

178. Nisar, S., Bhat, A. A., Hashem, S., Yadav, S. K., Rizwan, A., Singh, M., Bagga, P., Macha, M. A., Frenneaux, M. P., Reddy, R., and Haris, M. (2020). Non-Invasive Biomarkers for Monitoring the Immunotherapeutic Response to Cancer, *Journal of Translational Medicine*, Vol. 18, No. 1, 471. doi:10.1186/s12967-020-02656-7.

179. Abelin, J. G., Keskin, D. B., Sarkizova, S., Hartigan, C. R., Zhang, W., Sidney, J., Stevens, J., Lane, W., Zhang, G. L., Eisenhaure, T. M., Clauser, K. R., Hacohen, N., Rooney, M. S., Carr, S. A., and Wu, C. J. (2017). Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-Allelic Cells Enables More Accurate Epitope Prediction, *Immunity*, Vol. 46, No. 2, 315–326. doi:10.1016/j.immuni.2017.02.007.

180. Li, Y., Wu, X., Fang, D., and Luo, Y. (2024). Informing Immunotherapy with Multi-Omics Driven Machine Learning, *Npj Digital Medicine*, Vol. 7, No. 1, 1–16. doi:10.1038/s41746-024-01043-6.

181. Kumar, A., Dixit, S., Srinivasan, K., M, D., and Vincent, P. M. D. R. (2024). Personalized Cancer Vaccine Design Using AI-Powered Technologies, *Frontiers in Immunology*, Vol. 15, 1357217. doi:10.3389/fimmu.2024.1357217.

182. Jin, L., Zhou, Y., Zhang, S., and Chen, S.-J. (2025). mRNA Vaccine Sequence and Structure Design and Optimization: Advances and Challenges, *Journal of Biological Chemistry*, Vol. 301, No. 1, 108015. doi:10.1016/j.jbc.2024.108015.

183. Chen, H., Ren, X., Xu, S., Zhang, D., and Han, T. (2022). Optimization of Lipid Nanoformulations for Effective mRNA Delivery, *International Journal of Nanomedicine*, Vol. 17, 2893–2905. doi:10.2147/IJN.S363990.

184. Asrani, K. H., Farelli, J. D., Stahley, M. R., Miller, R. L., Cheng, C. J., Subramanian, R. R., and Brown, J. M. (2018). Optimization of mRNA Untranslated Regions for Improved Expression of Therapeutic mRNA, *RNA Biology*, Vol. 15, No. 6, 756–762. doi:10.1080/15476286.2018.1450054.

185. Uchikov, P., Khalid, U., Dedaj-Salad, G. H., Ghale, D., Rajadurai, H., Kraeva, M., Kraev, K., Hristov, B., Doykov, M., Mitova, V., Bozhkova, M., Markov, S., and Stanchev, P. (2024). Artificial Intelligence in Breast Cancer Diagnosis and Treatment: Advances in Imaging, Pathology, and Personalized Care, *Life*, Vol. 14, No. 11, 1451. doi:10.3390/life14111451.

186. Zhang, W.-Y., Zheng, X.-L., Coghi, P. S., Chen, J.-H., Dong, B.-J., and Fan, X.-X. (2024). Revolutionizing Adjuvant Development: Harnessing AI for next-Generation Cancer Vaccines, *Frontiers in Immunology*, Vol. 15. doi:10.3389/fimmu.2024.1438030.

187. Zheng, Y., Ma, Y., Xiong, Q., Zhu, K., Weng, N., and Zhu, Q. (2024). The Role of Artificial Intelligence in the Development of Anticancer Therapeutics from Natural Polyphenols: Current Advances and Future Prospects, *Pharmacological Research*, Vol. 208, 107381. doi:10.1016/j.phrs.2024.107381.

188. Bhinder, B., Gilvary, C., Madhukar, N. S., and Elemento, O. (2021). Artificial Intelligence in Cancer Research and Precision Medicine, *Cancer Discovery*, Vol. 11, No. 4, 900–915. doi:10.1158/2159-8290.CD-21-0090.

189. Hanna, M. G., Pantanowitz, L., Jackson, B., Palmer, O., Visweswaran, S., Pantanowitz, J., Deebajah, M., and Rashidi, H. H. (2025). Ethical and Bias Considerations in Artificial Intelligence/Machine Learning, *Modern Pathology*, Vol. 38, No. 3, 100686. doi:10.1016/j.modpat.2024.100686.

190. Stafie, C. S., Sufaru, I.-G., Ghiciuc, C. M., Stafie, I.-I., Sufaru, E.-C., Solomon, S. M., and Hancianu, M. (2023). Exploring the Intersection of Artificial Intelligence and Clinical Healthcare: A Multidisciplinary Review, *Diagnostics*, Vol. 13, No. 12, 1995. doi:10.3390/diagnostics13121995.

191. Kumar, A., Dixit, S., Srinivasan, K., M, D., and Vincent, P. M. D. R. (2024). Personalized Cancer Vaccine Design Using AI-Powered Technologies, *Frontiers in Immunology*, Vol. 15. doi:10.3389/fimmu.2024.1357217.

192. Doehn, C., Böhmer, T., Kausch, I., Sommerauer, M., and Jocham, D. (2008). Prostate Cancer Vaccines: Current Status and Future Potential, *BioDrugs*, Vol. 22, No. 2, 71–84. doi:10.2165/00063030-200822020-00001.

193. Redman, J. M., Gulley, J. L., and Madan, R. A. (2017). Combining Immunotherapies for the Treatment of Prostate Cancer, *Urologic Oncology*, Vol. 35, No. 12, 694–700. doi:10.1016/j.urolonc.2017.09.024.

194. Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., and Dong, C. (2023). Therapeutic Cancer Vaccines: Advancements, Challenges and Prospects, *Signal Transduction and Targeted Therapy*, Vol. 8, No. 1, 1–23. doi:10.1038/s41392-023-01674-3.

195. Chow, A., Perica, K., Klebanoff, C. A., and Wolchok, J. D. (2022). Clinical Implications of T Cell Exhaustion for Cancer Immunotherapy, *Nature Reviews Clinical Oncology*, Vol. 19, No. 12, 775–790. doi:10.1038/s41571-022-00689-z.

196. Madan, R. A., Antonarakis, E. S., Drake, C. G., Fong, L., Yu, E. Y., McNeel, D. G., Lin, D. W., Chang, N. N., Sheikh, N. A., and Gulley, J. L. (2020). Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T, *JNCI: Journal of the National Cancer Institute*, Vol. 112, No. 6, 562–573. doi:10.1093/jnci/djaa021.

197. Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., Tsang, K. Y., Poole, D. J., Parnes, H. L., Wright, J. J., Dahut, W. L., Schlom, J., and Gulley, J. L. (2012). Ipilimumab and a Poxviral Vaccine Targeting Prostate-Specific Antigen in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Dose-Escalation Trial, *The Lancet. Oncology*, Vol. 13, No. 5, 501–508. doi:10.1016/S1470-2045(12)70006-2.

198. McNeel, D. G., Eickhoff, J. C., Jeraj, R., Staab, M. J., Straus, J., Rekoske, B., and Liu, G. (2017). DNA Vaccine with Pembrolizumab to Elicit Antitumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)., *Journal of Clinical Oncology*, Vol. 35, No. 7_suppl, 168–168. doi:10.1200/JCO.2017.35.7_suppl.168.

199. Antonarakis, E. S., Kibel, A. S., Yu, E. Y., Karsh, L. I., Elfiky, A., Shore, N. D., Vogelzang, N. J., Corman, J. M., Millard, F. E., Maher, J. C., Chang, N. N., DeVries, T., Sheikh, N. A., and Drake, C. G. (2017). Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial, *Clinical Cancer Research*, Vol. 23, No. 10, 2451–2459. doi:10.1158/1078-0432.CCR-16-1780.

200. Small, E. J., Lance, R. S., Redfern, C. H., Millard, F. E., Gardner, T. A., Karsh, L. I., Dawson, N. A., McCoy, C., Stubbs, A., DeVries, T., Dela Rosa, C. P., Sheikh, N. A., and Shore, N. D. (2013). A Randomized Phase II Trial of Sipuleucel-T with Concurrent or Sequential Abiraterone Acetate (AA) plus Prednisone (P) in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)., *Journal of Clinical Oncology*, Vol. 31, No. 15_suppl, 5047–5047. doi:10.1200/jco.2013.31.15_suppl.5047.

201. Podrazil, M., Horvath, R., Becht, E., Rozkova, D., Bilkova, P., Sochorova, K., Hromadkova, H., Kayserova, J., Vavrova, K., Lastovicka, J., Vrabcova, P., Kubackova, K., Gasova, Z., Jarolim, L., Babjuk, M., Spisek, R., Bartunkova, J., and Fucikova, J. (2015). Phase I/II Clinical Trial of Dendritic-Cell Based Immunotherapy (DCVAC/PCa) Combined with Chemotherapy in Patients with Metastatic, Castration-Resistant Prostate Cancer, *Oncotarget*, Vol. 6, No. 20, 18192–18205. doi:10.18632/oncotarget.4145.

202. Vogelzang, N. J., Beer, T. M., Gerritsen, W., Oudard, S., Wiechno, P., Kukielka-Budny, B., Samal, V., Hajek, J., Feyerabend, S., Khoo, V., Stenzl, A., Csöszi, T., Filipovic, Z., Goncalves, F., Prokhorov, A., Cheung, E., Hussain, A., Sousa, N., Bahl, A., Hussain, S., Fricke, H., Kadlecova, P., Scheiner, T., Korolkiewicz, R. P., Bartunkova, J., Spisek, R., VIABLE Investigators, Stadler, W., Berg, A. S., Kurth, K.-H., Higano, C. S., Aapro, M., Krainer, M., Hruby, S., Meran, J., Polyakov, S., Machiels, J.-P., Roumeguere, T., Ackaert, K., Lumen, N., Gil, T., Minchev, V., Tomova, A., Dimitrov, B., Koleva, M., Juretic, A., Fröbe, A., Vojnovic, Z., Drabek, M., Jarolim, L., Buchler, T., Kindlova, E., Schraml, J., Zemanova, M., Prausova, J., Melichar, B., Chodacka, M., Jansa, J., Daugaard, G., Delonchamps, N., Duclos, B., Culine, S., Deplanque, G., Le Moulec, S., Hammerer, P., Rodemer, G., Ritter, M., Merseburger, A., Grimm, M.-O., Damjanoski, I., Wirth, M., Burmester, M., Miller, K., Herden, J., Keck, B., Wuelfing, C., Winter, A., Boegemann, M., Von Schmeling, I. K., Fornara, P., Jaeger, E., Bodoky, G., Pápai, Z., Böszörményi-Nagy, G., Vanella, P., SotoParra, H., Passalacqua, R., Ferrau, F., Maio, M., Fratino, L., Cortesi, E., Purkalne, G., Asadauskiene, J., Janciauskiene, R., Tulyte, S., Cesas, A., Polee, M., Haberkorn, B., Van De Eertwegh, F., Van Den Berg, P., Beeker, A., Nieboer, P., Zdrojowy, R., Staroslawska, E., Fijuth, J., Sikora-Kupis, B., Karaszewska, B., Fernandes, I., Sousa, G., Rodrigues, T., Dzamic, Z., Babovic, N., Cvetkovic, B., Sokol, R., Mikuláš, J., Gajdos, M., Brezovsky, M., Mincik, I., Breza, J., Arranz, J. A., Calvo, V., Rubio, G., Chapado, M. S., Boreu, P. G., Montesa, A., Olmos, D., Mellado, B., Castellano, D., Puente, J., Karlsson, E. T., Ahlgren, J., Pandha, H., Mazhar, D., Vilarino-Varela, M., Elliott, T., Pedley, I., Zarkar, A., Law, A., Slater, D., Karlin, G., Bilusic, M., Redfern, C., Gaur, R., McCroskey, R., Clarkson, D., Agrawal, M., Shtivelband, M., Nordquist, L., Karim, N., Hauke, R., Flaig, T., Jhangiani, H., Singal, R., Choi, B., Reyes, E., Corman, J., Hwang, C., Appleman, L., McClay, E., Fleming, M., Gunuganti, V., Cheung, E., Gartrell, B., Sartor, A., Williamson, S., Gandhi, J., Schnadig, I., Burke, J., Bloom, S., Shore, N., Mayer, T., Oh, W., Bryce, A., Belkoff, L., Vaishampayan, U., Agarwala, S., Kucuk, O., Agrawal, A., Walsh, W., Poiesz, B., Harshman, L., Dawson, N., and Sharma, S. (2022).

Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial, *JAMA Oncology*, Vol. 8, No. 4, 546. doi:10.1001/jamaoncol.2021.7298.

203. Kongsted, P., Borch, T. H., Ellebaek, E., Iversen, T. Z., Andersen, R., Met, Ö., Hansen, M., Lindberg, H., Sengeløv, L., and Svane, I. M. (2017). Dendritic Cell Vaccination in Combination with Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase II Study, *Cytotherapy*, Vol. 19, No. 4, 500–513. doi:10.1016/j.jcyt.2017.01.007.

204. Li, C., Sun, H., Wei, W., Liu, Q., Wang, Y., Zhang, Y., Lian, F., Liu, F., Li, C., Ying, K., Huo, H., Qi, Z., and Li, B. (2020). Mitoxantrone Triggers Immunogenic Prostate Cancer Cell Death via P53-Dependent PERK Expression, *Cellular Oncology (Dordrecht, Netherlands)*, Vol. 43, No. 6, 1099–1116. doi:10.1007/s13402-020-00544-2.

205. Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., and Zhang, Z. (2023). Chemotherapeutic and Targeted Drugs-Induced Immunogenic Cell Death in Cancer Models and Antitumor Therapy: An Update Review, *Frontiers in Pharmacology*, Vol. 14. doi:10.3389/fphar.2023.1152934.

206. Garnett-Benson, C., Hodge, J. W., and Gameiro, S. R. (2015). Combination Regimens of Radiation Therapy and Therapeutic Cancer Vaccines: Mechanisms and Opportunities, *Seminars in Radiation Oncology*, Vol. 25, No. 1, 46–53. doi:10.1016/j.semradonc.2014.07.002.

207. Cadena, A., Cushman, T., Anderson, C., Barsoumian, H., Welsh, J., and Cortez, M. (2018). Radiation and Anti-Cancer Vaccines: A Winning Combination, *Vaccines*, Vol. 6, No. 1, 9. doi:10.3390/vaccines6010009.

208. Gulley, J. L., Arlen, P. M., Bastian, A., Morin, S., Marte, J., Beetham, P., Tsang, K.-Y., Yokokawa, J., Hodge, J. W., Ménard, C., Camphausen, K., Coleman, C. N., Sullivan, F., Steinberg, S. M., Schlom, J., and Dahut, W. (2005). Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer, *Clinical Cancer Research*, Vol. 11, No. 9, 3353–3362. doi:10.1158/1078-0432.CCR-04-2062.

209. Mondini, M., Nizard, M., Tran, T., Mauge, L., Loi, M., Clémenson, C., Dugue, D., Maroun, P., Louvet, E., Adam, J., Badoual, C., Helley, D., Dransart, E., Johannes, L., Vozenin, M.-C., Perfettini, J.-L., Tartour, E., and Deutsch, E. (2015). Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer, *Molecular Cancer Therapeutics*, Vol. 14, No. 6, 1336–1345. doi:10.1158/1535-7163.MCT-14-1015.

210. Korbelik, M. (2022). Radiovaccination Strategy for Cancer Treatment Integrating Photodynamic Therapy-Generated Vaccines with Radiotherapy, *International Journal of Molecular Sciences*, Vol. 23, No. 20, 12263. doi:10.3390/ijms232012263.

211. Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., White, C., Lowe, C., Sherba, J. J., Hartmanshenn, C., O'Neill, K. M., Balter, M. L., Fritz, Z. R., Androulakis, I. P., Schloss, R. S., and Yarmush, M. L. (2018). The Growing Role of Precision and Personalized Medicine for Cancer Treatment, *Technology*, Vol. 6, Nos. 3–4, 79–100. doi:10.1142/S2339547818300020.

212. Anassi, E., and Ndefo, U. A. (2011). Sipuleucel-T (Provenge) Injection, *Pharmacy and Therapeutics*, Vol. 36, No. 4, 197–202.

213. Jönsson, B., and Wilking, N. (2012). Cancer Vaccines and Immunotherapeutics, *Human Vaccines & Immunotherapeutics*, Vol. 8, No. 9, 1360–1363. doi:10.4161/hv.21921.

214. Lorgelly, P., Pollard, J., Cubi-Molla, P., Cole, A., Sim, D., and Sussex, J. (2020). Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value?, *The Patient*, Vol. 13, No. 5, 599–610. doi:10.1007/s40271-020-00430-x.

215. Kwilas, A. R., Gameiro, S. R., Kim, P. S., Malamas, A. S., and Hodge, J. W. (2015). Improving Clinical Benefit for Prostate Cancer Patients through the Combination of Androgen Deprivation and Immunotherapy, *Oncoimmunology*, Vol. 4, No. 6, e1009303. doi:10.1080/2162402X.2015.1009303.

216. Yang, C., Jin, J., Yang, Y., Sun, H., Wu, L., Shen, M., Hong, X., Li, W., Lu, L., Cao, D., Wang, X., Sun, J., Ye, Y., Su, B., and Deng, L. (2022). Androgen Receptor-Mediated CD8+ T Cell Stemness Programs Drive Sex Differences in Antitumor Immunity, *Immunity*, Vol. 55, No. 7, 1268-1283.e9. doi:10.1016/j.immuni.2022.05.012.

217. Muralidhar, A., Gamat-Huber, M., Vakkalanka, S., and McNeel, D. G. (2024). Sequence of Androgen Receptor-Targeted Vaccination with Androgen Deprivation Therapy Affects Anti-Prostate Tumor Efficacy, *Journal for ImmunoTherapy of Cancer*, Vol. 12, No. 5, e008848. doi:10.1136/jitc-2024-008848.

218. Long, X., Hou, H., Wang, X., Liu, S., Diao, T., Lai, S., Hu, M., Zhang, S., Liu, M., and Zhang, H. (2020). Immune Signature Driven by ADT-Induced Immune Microenvironment Remodeling in Prostate Cancer Is Correlated with Recurrence-Free Survival and Immune Infiltration, *Cell Death & Disease*, Vol. 11, No. 9, 779. doi:10.1038/s41419-020-02973-1.

219. Deng, Z., Tian, Y., Song, J., An, G., and Yang, P. (2022). mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy, *Frontiers in Immunology*, Vol. 13, 887125. doi:10.3389/fimmu.2022.887125.

220. Colluru, V. T., Johnson, L. E., Olson, B. M., and McNeel, D. G. (2016). Preclinical and Clinical Development of DNA Vaccines for Prostate Cancer, *Urologic Oncology*, Vol. 34, No. 4, 193–204. doi:10.1016/j.urolonc.2013.09.014.

221. Sardesai, N. Y., and Weiner, D. B. (2011). Electroporation Delivery of DNA Vaccines: Prospects for Success, *Current Opinion in Immunology*, Vol. 23, No. 3, 421–429. doi:10.1016/j.coi.2011.03.008.

222. Kisakov, D. N., Belyakov, I. M., Kisakova, L. A., Yakovlev, V. A., Tigeeva, E. V., and Karpenko, L. I. (2024). The Use of Electroporation to Deliver DNA-Based Vaccines, *Expert Review of Vaccines*, Vol. 23, No. 1, 102–123. doi:10.1080/14760584.2023.2292772.

223. Shah, K., Ganapathy, A., Borkowski, A., Shah, N., Bansal, D., Beck, R., Knoche, E. M., Picus, J., Reimers, M. A., Roth, B. J., Gulley, J. L., Schreiber, R., and Pachynski, R. K. (2022). A Pilot Trial of Neoantigen DNA Vaccine in Combination with Nivolumab/Ipilimumab and Prostvac in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)., *Journal of Clinical Oncology*, Vol. 40, No. 16_suppl, 5068–5068. doi:10.1200/JCO.2022.40.16_suppl.5068.

224. O'Cathail, S. M., Pokrovska, T. D., Maughan, T. S., Fisher, K. D., Seymour, L. W., and Hawkins, M. A. (2017). Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization, *Frontiers in Oncology*, Vol. 7, 153. doi:10.3389/fonc.2017.00153.

225. Dias, J. D., Hemminki, O., Diaconu, I., Hirvinen, M., Bonetti, A., Guse, K., Escutenaire, S., Kanerva, A., Pesonen, S., Löskog, A., Cerullo, V., and Hemminki, A. (2012). Targeted Cancer Immunotherapy with Oncolytic Adenovirus Coding for a Fully Human Monoclonal Antibody Specific for CTLA-4, *Gene Therapy*, Vol. 19, No. 10, 988–998. doi:10.1038/gt.2011.176.

226. Ren, Y., Miao, J.-M., Wang, Y.-Y., Fan, Z., Kong, X.-B., Yang, L., and Cheng, G. (2022). Oncolytic Viruses Combined with Immune Checkpoint Therapy for Colorectal Cancer Is a Promising Treatment Option, *Frontiers in Immunology*, Vol. 13. doi:10.3389/fimmu.2022.961796.

227. Li, X., You, J., Hong, L., Liu, W., Guo, P., and Hao, X. (2024). Neoantigen Cancer Vaccines: A New Star on the Horizon, *Cancer Biology & Medicine*, Vol. 21, No. 4, 274–311. doi:10.20892/j.issn.2095-3941.2023.0395.

228. Zelba, H., Rabsteyn, A., Bartsch, O., Kyzirakos, C., Kayser, S., Seibold, M., Harter, J., Latzer, P., Hadaschik, D., Battke, F., Golf, A., Rettig, M. B., and Biskup, S. (2023). Case Report: Targeting of Individual Somatic Tumor Mutations by Multipeptide Vaccination Tailored for HLA Class I and II Presentation Induces Strong CD4 and CD8 T-Cell Responses in a Patient with Metastatic Castration

Sensitive Prostate Cancer, *Frontiers in Immunology*, Vol. 14, 1271449. doi:10.3389/fimmu.2023.1271449.

229. Kumar, A., Dixit, S., Srinivasan, K., M, D., and Vincent, P. M. D. R. (2024). Personalized Cancer Vaccine Design Using AI-Powered Technologies, *Frontiers in Immunology*, Vol. 15. doi:10.3389/fimmu.2024.1357217.

230. Satheeskumar, R. (2025). AI-Driven Diagnostics and Personalized Treatment Planning in Oral Oncology: Innovations and Future Directions, *Oral Oncology Reports*, Vol. 13, 100704. doi:10.1016/j.oor.2024.100704.

231. Zhou, D., Nakamura, M., Mukumoto, N., Tanabe, H., Iizuka, Y., Yoshimura, M., Kokubo, M., Matsuo, Y., and Mizowaki, T. (2022). Development of AI-Driven Prediction Models to Realize Real-Time Tumor Tracking during Radiotherapy, *Radiation Oncology*, Vol. 17, No. 1, 42. doi:10.1186/s13014-022-02012-7.

232. Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., and Ganjalikhani-hakemi, M. (2021). mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients, *Vaccines*, Vol. 9, No. 10, 1060. doi:10.3390/vaccines9101060.

233. Zhang, Y., You, P., Liu, R., Lu, Y., Li, J., Lei, Y., Wu, S., and Zhou, H. (2025). Artificial Intelligence in Clinical Trials of Lung Cancer: Current and Future Prospects, *Intelligent Oncology*, Vol. 1, No. 1, 34–51. doi:10.1016/j.intonc.2024.11.003.

234. Kannan, S., Subbaram, K., and Faiyazuddin, Md. (2023). Chapter 17 - Artificial Intelligence in Vaccine Development: Significance and Challenges Ahead, A. Philip; A. Shahiwala; M. Rashid; Md. Faiyazuddin (Eds.), *A Handbook of Artificial Intelligence in Drug Delivery*, Academic Press, 467–486. doi:10.1016/B978-0-323-89925-3.00017-4.